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Alzheimer’s disease is a debilitating neurological disorder, the worldwide cost 
of which has recently entered into the trillions of dollars ($USD) per annum. 
The primary cause of Alzheimer’s disease is believed to be the accumulation in 
the brain of amyloid beta (Aβ), a protein product of the Amyloid Precursor 
Protein (APP) processing pathway. The increasing concentration of Aβ 
facilitates aggregation, which generates a number of neurologically harmful 
products, and causes a collection of symptoms, primarily dementia, which are 
collectively known as Alzheimer’s disease. In the normal cellular environment, 
it is suspected that there are neuroprotective pathways that act to counter this 
accumulation of Aβ. One such pathway is mediated by a soluble product of 
APP processing called sAPPα. sAPPα has been shown to bind to Aβ in vitro 
and also to rescue early stage Alzheimer’s phenotype in mouse models.  It is of 
significant interest for the development of a therapy against Alzheimer’s 
disease in humans. It is, however, not currently known to which Aβ aggregated 
state sAPPα interacts as Aβ can aggregate into a multitude of forms with 
differing levels of pathogenicity. It is therefore crucial to understand how 
sAPPα might counter Aβ toxicity by characterising this binding relationship 
and thereby deucing how it might be used in a future therapy against 
Alzheimer’s. 
In this study I produced recombinant human sAPPα in bacteria as a fusion 
protein with a glutathione transferase (GST) N terminal tag and purified it by 
affinity chromatography using the GST tag to bind to glutathione on a column. 
Pure GST –sAPPα was immobilised on the glutathione column as a solid phase. 
GST-sAPPα was exposed to a mixture containing non-aggregated and 
aggregated forms of Aβ. Species within this mixture interacted and co-eluted 
with GST-sAPPα after addition of exogenous glutathione. The critical question 
then was which form of Aβ interacts with sAPPα? The mixture of aggregate 
forms was therefore fractionated, first by centrifugation, and then more 
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definitively by FPLC on a size exclusion column. As an initial test for which 
form of Aβ bound to sAPPα, nitrocellulose membrane was used to facilitate a 
detection assay for the ability of different species (monomer, dimer, trimer and 
soluble higher-order oligomers) to bind to immobilised GST-sAPPα. These 
binding membranes were probed with antibodies specific to a sequence shared 
by both sAPPα and Aβ, to measure enhancement of signal by addition of the 
Aβ species.  
 
Using computer analysis with ImageJ, it was possible to directly compare the 
levels of fluorescence, relative to the negative controls, which allowed the 
relative levels of binding between the different aggregate forms of Aβ to be 
compared. 
It was found using these methods that the predominant binding partner of 
sAPPα in vitro are the soluble higher-order aggregates, but that monomeric, and 
dimeric/trimeric forms of Aβ also showed some binding capacity. However, a 
better detection assay needs to be developed.  
 This study supports a binding relationship between sAPPα and Aβ and the 
potential for the development of a therapy utilising the action of sAPPα to 
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1.1 Amyloid precursor protein 
 
The amyloid precursor protein gene or “APP” is highly conserved throughout a 
wide range of species and expressed in most human tissues, but concentrated 
predominantly in the central nervous system and the brain. (Uhlén et al., 2015) 
APP is implicated in a number of neurological processes – including memory 
and general brain development as well as both the cause and (putatively) the 
protective mechanism against the symptoms of Alzheimer’s disease. In humans, 
it is located on chromosome 21 (21q21.3) and is approximately 240 kilobases 
long, containing 18 exons (Yoshikai et al., 1990). Typically in mammals, APP 
has been found to be part of a gene family, which also includes homologues: 
APLP1 and APLP2 (Amyloid precursor like protein 1 and 2 respectively) 
(Sprecher et al., 1993) (Dyrks et al., 1988). Together these genes are thought to 
have roles in the development and formation of synapses as well as their 
ongoing function.  
 
The promoter of APP is fairly typical of a housekeeping gene in that it contains 
no identifiable TATA box, has a very high GC content (72%) and has multiple 
transcription start sites (Salbaum et al., 1988). The APP gene itself encodes a 
single-pass type-I integral transmembrane protein (Kang et al., 1987). The 
primary transcript is known to undergo several splicing events resulting in the 
translation of a number of APP protein isoforms. The synthesized protein also 
undergoes a large number of post-translational modifications before it is 
inserted into the membrane. The main isoform that is produced by the APP 
gene in human neural cells is APP695. It lacks exons 7 and 8 of the full APP 
gene and is as the name suggests 695 residues long (Tanaka et al., 1989) 
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(Zhang et al., 2011). Due to its prevalence in the human brain, it is also the 
isoform of most interest to Alzheimer’s disease research. 
 
Fig. 1.1: Structure of the APP695 protein showing the domains of the 
protein and the positions of its major protein products: sAPPα, sAPPβ and 
Aβ. This figure re-used with permission from John Wiley and Sons. Figure 
source: Chasseigneaux and Allinquant, 2012 
 
Despite rigorous investigation and identification of the function of several post-
translation derivative forms, the function of the whole parent APP protein 
before modification is still not entirely understood. A number of proposed roles 
and functions have been suggested based on the characteristics of the domains 
present in the protein, but these are still largely speculative (Dawkins and 
Small, 2014).  
 
The structure of APP suggests that it may have a similar role to the Notch 
protein signalling pathway and it therefore its major function is as a cell 
signalling molecule. The Notch cell signalling pathway is composed of another 
evolutionarily conserved cell-surface protein family whose general function 
helps to determine cell fates in developing organisms. It was named due to the 
characteristic ‘notches’ it produces in the wings of flies with partial loss of 
function of the gene. Similarly to APP, Notch RNA and proteins undergo a 
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variety of pre and post-translational modifications that help to specialise and 
define the function of its products (Artavanis-Tsakonas, Rand and Lake. 1999). 
Supporting the theory of APP and Notch similarity, a number of ligands for 
membrane-bound APP have been identified; including Aβ (Lorenzo et al., 
2000), F-spondin (Ho and Südhof, 2004) and nectrin-1 (Lourenco et al., 2009). 
 
It was thought and later confirmed by experimental data that the homologues of 
APP: APLP1 and APLP2 can compensate for the knockout or loss of APP and 
therefore are confounding factors for any research into the function of APP 
itself. A triple knockout of all three genes in mice models produces phenotypes 
with cranial abnormalities that resemble human type 2 lissencephaly; a 
condition where the brain fails to fold correctly and has a smooth appearance 
(Herms et al., 2004). This results in a number of symptoms in humans including 
seizures and intellectual impairment, with the life expectancy of sufferers 
averaging approximately 10 years.  Mouse models by contrast died shortly after 
birth. This study shows that this gene family plays a crucial role in 
development, potentially in the formation of the basal lamina (Herms et al., 
2004). Neurons have been shown to differentiate without the presence of this 
gene family, at least in-vitro (Bergmans et al., 2010). 
 
The main area of interest in the APP protein for my project is its part in the 
development of Alzheimer’s disease. The APP protein post-insertion in the 
cellular membrane can undergo one of two proteolytic cleavage pathways that 
produce a number of products with distinctly different functions and thereby 






Fig. 1.2: Cleavage sites in the APP protein and their resultant products.  
This figure re-used with permission from John Wiley and Sons. Figure source: 
Chasseigneaux and Allinquant, 2012 
 
These pathways are mediated by the cleavage of the APP protein by one of two 
proteolytic enzymes – termed α-secretase or β-secretase. Cleavage by either 
secretase produces a sAPP protein (secreted Amyloid Precursor Protein) – 
sAPPα in the case of α-secretase and a slightly shorter protein sAPPβ in the 
case of β-secretase – this α or β cleavage is then followed by a γ-secretase 
cleavage of the remaining membrane bound domain. Both pathways produce a 
fragment that has a short cytoplasmic domain, AICD, which is further 
processed into Jcasp and C31 both of which are neurotoxic and cytotoxic 
protein products (Zhang et al., 2011).  
 
Where these pathways differ however, is that if the initial cleavage is at the α 
site of APP to produce a large N terminal fragment sAPPαthen the remaining 
protein fragment is processed into p83 – thought to be degraded quickly and 
possessing of no important function – if the initial product were fragment 
sAPPβ by cleavage at the β site in APP, however, the remaining C terminal is 
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processed into Aβ – a peptide of 40-43 amino acids whose significance will be 
explained later (Zhang et al., 2011).  
Interestingly, a mutation in an allele of APP has been identified particularly in 
the Icelandic human population that has been found to have a strong effect on 
the protection of its host from the development of Alzheimer’s disease (Jonsson 
et al., 2012). The mutation, dubbed “The Icelandic mutation” due to its 
discovery and prevalence in Iceland, is in position 673 in the nucleotide 
sequence of the APP gene and takes the form of an A to T substitution. This 
mutation interferes directly with the ability of β-secretase to cleave the APP 
protein, which promotes the action of the α-secretase pathway and results in a 
40% reduction of Aβ observable in vivo (Jonsson et al., 2012). 
In terms of a clinical effect, the prevalence of Alzheimer’s disease, advanced or 
otherwise, is much lower in sections of populations with this mutation. As well 
as this, remarkably it was found that those with this allele had better cognitive 
function into very advanced age when compared with healthy controls without 
this allele – suggesting that the perhaps the other APP protein, sAPPα has a role 
in the normal function or at least preservation of long-term potentiation and 











sAPPα, as previously mentioned, is one of the proteolytic cleavage products of 
APP processing by α-secretase at the α site in the APP molecule. It is an 
Alzheimer’s-associated protein that has provoke much interest with regards to 
the development of future therapies to delay, slow, or even prevent the onset of 
Alzheimer’s disease.  
In terms of structure, sAPPα is 612 amino acids long and contains 12 cysteines, 
it contains three disulphide bonds which help to determine its secondary 
structure (Rossjohn et al., 1999). The main domains of sAPPα appear to all be 
heparin binding sites – but they are also able to bind other important moieties, 
for example one is able to bind to copper, one to zinc and one to a growth factor 
(Chasseigneaux and Allinquant, 2012).  
Additionally, sAPPα is well known to have a neuroprotective function in a wide 
range of species. Transgenic mice that overexpress APP in their neurons 
display enhanced aggression, behaviour deficits, early death, aberrant reactions 
to kainic acid (a neuroexcitatory amino acid) and NMDA, reduced grip 
strength, reduced brain and body weight and difficulty with spacial recognition. 
These effects were rescuable with the knock-in of a functional sAPPα gene 
fragment (Moechars et al., 1996, 1998) (Ring et al., 2007).  
In conjunction with heparan sulphate proteoglycans, sAPPα has also 
demonstrated the ability to stimulate neurite outgrowth in both mouse and chick 
models (Small et al., 1994) (Clarris et al., 1994, 1997). Likewise, research into 
the N terminal residues 18-350 of sAPPα have identified growth factor domains 
that appear to act to encourage the proliferation of fibroblast cells, thyroid 
epithelial cells and neural stem cells in developing brains (Saitoh et al., 1989) 
(Pietrzik et al., 1998) (Hayashi et al., 1994) (Ohsawa et al., 1999). 
One of the more interesting roles of sAPPα is its role in the process of long-
term potentiation (LTP), which refers to a neuronal process whereby two 
neurons are stimulated synchronously. LTP enhances signal transduction of 
these neurons and is widely believed to be the most important neural process 
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mediating learning and long-term memory (Bliss and Collingridge, 1993) 
(Cooke and Bliss, 2006). sAPPα appears to have a role in this process in mouse 
models, both normal and amnestic; sAPPα appears to have a positive effect on 
learning and memory and no perceivable negative effects (Roch et al., 1994) 
(Meziane et al., 1998). Later studies have shown that the addition of sAPPα 
generally acts to increase memory ability and is even enough to completely 
restore the impairments in learning resulting from APP knockout in these mice 
models (Ring et al., 2007).  
If production of sAPPα in vivo is prevented by an inhibitor of the α secretase 
(Tumour necrosis associated protein Inhibitor –TAPI), memory mechanisms 
like LTP are lost as well as ability to complete learning tasks in a water maze. 
but these functions can be restored by infusing into the brains of animals 
recombinant sAPPα produced in human kidney cells (Taylor et al., 2008) 
sAPPα, has a neuroprotective function in the neural environment, and the 
terminal 16 amino acids to protect against such neural dangers as glutamate 
toxicity, Aβ aggregation-induced oxidative damage as well as glucose 
starvation (Mattson et al., 1993) (Goodman and Mattson, 1994) (Barger and 
Harmon, 1997) (Turner et al., 2007) (Mukadam 2009).  These terminal 16 
amino acids also enhance LTP in hippocampal slices to the same extent as the 
parent sAPPα molecule (Morrissey et al., 2019) 
 
The exact mechanism behind these neuroprotective and memory functions, as 
with many of the functions of APP and its derivatives is still not completely 
understood. The neuroprotective action has been localised to the terminal 16 
amino acids, via studies that compare the relative effects of altering levels of 
sAPPα and sAPPβ in neurological models. sAPPβ lacks the terminal 16 amino 
acid sequence and therefore has been used comparitively with sAPPα in studies 
of its function (Furukawa et al., 1996) (Barger and Harmon, 1997) (Turner et 
al., 2007) (Morissey et al., 2019). 
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Two domains within sAPPα capable of binding heparan sulphate proteoglycans 
have recently been shown to protect against severe brain damage in rat models 
– which may suggest that similarly to the neurite outgrowth role of sAPPα, 
these neuroprotective events are likewise mediated by these domains (Corrigan 




sAPPβ is a 596-residue protein that is cleaved by β-secretase in one of the 
aforementioned proteolytic pathways of APP. In terms of structure, it shares 
sequence homology with the majority of sAPPα, with the exception of the last 
16 amino acids of sAPPα, which as mentioned are not present in sAPPβ being 
cleaved to form the leading 16 amino acids of Aβ. This has been shown to 
affect the overall conformation of the sAPPs and this may be the reason the two 
closely related proteins have such different functions. Peters-Libeu et al., 2015 
showed a conformational difference that meant sAPPα could bind to the β-
secretase affecting Aβ production whereas the conformation adopted by sAPPβ 
was not inhibitory. 
This sequence and possible conformational difference appear to have a large 
effect on the action of the sAPPβ protein – whose neuroprotective effects 
against problems such as excitotoxicity and Aβ action are reduced 50 to 100-
fold, further suggesting that the last 16 amino acids of sAPPα are critical for the 
mechanisms of its neuroprotection (Furukawa et al., 1996) (Barger and 
Harmon, 1997) (Turner et al., 2007). 
This is further supported by the fact that mouse models with the APP gene 
knocked out are unable to be rescued from the resultant deficiencies in learning 
and memory by the knock in of sAPPβ (Li et al., 2010) (Weyer et al., 2011) –
compared to sAPPα knock in that can rescue neuroprotection in similar 
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experiments. Those functions of sAPPα that are not mediated by the C-terminal 
16 amino acids, such as neural proliferation and outgrowth, appear to be 
unhindered in sAPPβ however (Chasseigneaux and Allinquant, 2012), further 
suggesting that these functions are due to the heparin sulphate proteoglycan 
binding domains that are present in both sAPPα and sAPPβ. Both sAPPα and 
sAPPβ can equally stimulate proliferation of neural progenitor cells from the 
hippocampus and their differentiation, functions clearly mediated by domains 
in common within the two molecules (Baratchi et al., 2012). 
 
1.2.3 Amyloid Beta (Aβ) 
 
Aβ is the proteolytic product that has generated most interest among the 
neuroscience research community interested in Alzheimer’s disease. Aβ can 
vary in length from 40-43 amino acids, but its two most common forms have 40 
and 42 amino acids and have a mass of approximately 4 kilodaltons (Gregory 
and Halliday, 2005). In the normal cellular environment, monomeric forms of 
Aβ have been proposed to have a variety of roles in neuroprotection – which 
seems logical due to the fact that as previously mentioned Aβ has the 16 amino 
acid chain that appears to be the predominant factor in the neuroprotective 
properties of sAPPα (Whitson, Selkoe and Cotman, 1989) (Giuffrida et al., 
2009) Aβ has also been linked with antioxidant ability, protecting neurons from 
oxidative damage as well as performing a negative feedback regulation role in 
day to day synaptic activity (Zou et al., 2002) (Kamenetz et al., 2003). Aβ has 
also been found to be the primary factor in the development and ongoing 
pathogenesis of Alzheimer’s disease and therefore is of particular interest to 
researchers and health workers that are working to understand the nature of this 
increasingly common neurological disease. 
A distinction must be made between the monomeric form of Aβ and the dimers 
and higher order oligomers that it can form in the pathogenesis of Alzheimer’s 
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disease. While monomeric Aβ appears to have a variety of functional 
physiological effects in the neuronal environment, when it begins to generate 
dimers, trimers and higher order oligomers; the mechanism of dimerisation 
produces reactive oxygen species that can directly damage the neurons 
themselves (Mattson, 2004). Additionally; there are further damaging effects to 
neurons and networks from the accumulation of higher order aggregates of Aβ 
causes. 
Aβ can influence the balance of APP secretase processing pathways to further 
promote production of itself. This in turn has a variety of negative effects on the 
health of the cells involved and can act to further the pathogenesis of 
Alzheimer’s disease (Libeu et al., 2011). It appears that it is the initiation of 
aggregation of Aβ that is the instigator of the first stages of Alzheimer’s 
disease, however, the factors that cause this process to happen are currently 
unclear. Some factors have been proposed such as: genetic changes to the APP 
gene that favour the β-secretase pathway and thereby accumulation of Aβ, as 
well as environmental factors that could likewise help seed that first step of Aβ 
aggregation.  
There is evidence as well that much of the pathology and development of 
Alzheimer’s disease is due to signalling processes that are activated by Aβ and 
its soluble oligomers. It has been found that at least two Aβ isomers are able to 
bind to the APP protein ectodomain and therefore cause changes in the 
conformation and oligomerisation state of the protein (Libeu et al., 2011). This 
binding and subsequent conformational change in the APP protein causes a 
reduction in the ability of α-secretase to proteolytically cleave the APP protein, 
meaning that less sAPPα is produced. This in turn allows for a higher 
production of Aβ, allowing for more Aβ-APP complexes to be formed and 
continuing the cycle of Aβ accumulation (Libeu et al., 2011). Extracellular 
uptake of Aβ oligomers appears to occur through a variety of discrete cell 
receptors such as: NMDA receptor, alphaamino-3-hydroxyl-5-methyl-4-
isoxazole-propionate receptors, low-density lipoprotein receptor-related protein, 
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alpha7 nicotinic acetylcholine receptor, and receptor for advanced glycation end 
products – however it does not appear that monomeric forms of Aβ are able to 
enter the cell in this manner (Giri et al., 2000) (Wang et al., 2000) (Bi et al., 
2002) (Bu, Cam and Zerbinatti, 2006) (Zhao et al., 2010). 
 
1.3 Alzheimer’s disease 
 
Dementia is a serious neurological condition that affects the cognition of its 
sufferers – often through the degradation of neural tissue and its associated 
effects. These effects can vary from person to person due to many stochastic 
factors and environmental effects but in general dementia is associated with a 
reduction in: memory, comprehension, learning capacity and judgment 
(Duthey, 2013) (Prince et al., 2014). 
Alzheimer’s disease is the most common cause of dementia worldwide and 
affects up to 10% of the population over age 65 and as much as 50% of the 
population over age 85 (Prince et al., 2014). Originally detected in 1906 by 
Alois Alzheimer, the disease itself was confirmed in post-mortem as 
manifesting in the brains of the affected as neuritic plaques: extracellular 
protein masses which are able to disrupt the delicate neuronal connections, as 
well as neurofibrillary tangles, intracellular helical protein structures that 
disrupt normal function. These factors were in concert are thought to interfere 
with the normal function of the brain itself (Prince et al., 2014). These masses 
of protein putatively interfere with neuronal connections and therefore brain 
function. However, it has been theorised that the generation of reactive oxygen 
species by the aggregation mechanism is the contributor to the most severe of 
the neurological damage observed in Alzheimer's disease. Higher order 
aggregates, according to this line of thought, are more of a natural consequence 
of the development of the disease rather than the main pathological element (Du 
et al., 2011). 
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The peptide responsible for these aggregates, Aβ, was identified nearly eighty 
years after the disease itself and the physical masses were first described 
(Masters et al., 1985) and despite the huge research effort its functions and the 
effects of its accumulation in the brain are still not fully understood – however 
it remains to be thought of as the causative agent in the development of 
Alzheimer’s disease. The predisposition towards developing Alzheimer’s 
disease via accumulation of Aβ can be due to familial factors, mutation or most 
commonly stochastic events in the neurological environment.  
Alzheimer’s disease has a well-defined timeline of effects, the time course of 
which averages roughly 7-10 years. Although there is likely a symptomless 10-
20 year period, once symptoms become apparent it follows closely to general 
dementia symptoms – starting with impaired memory in the early stages of the 
disease and progressing through visual and spatial recognition errors, loss of 
language ability and even changes in personality. As the disease enters its late 
stages, patients require full time care and are unable to speak, move without 
assistance and generally suffer from loss of other physiological functions, 
exhibiting incontinence and involuntary bowel movements (McKhann et al., 
1984) (Duthey, 2013) (Alzheimer’s Disease International., 2014). 
Alzheimer’s disease is very quickly becoming a serious concern at both the 
individual level and societal level. At the individual level, factors such as 
increased lifespan as well as behavioural changes with a modern lifestyle are 
increasing the incidence of Alzheimer’s disease worldwide. 
Alzheimer’s Disease International estimates that over 46 million people 
currently live with dementia, of which Alzheimer’s disease is the most common 
cause (Prince et al., 2015). This number from the 2015 analysis was expected to 
double every 20 years, reaching 74.7 million by 2030 and 131.5 million people 
with dementia at 2050. In 2018, this number was estimated to have reached 50 
million people worldwide and constantly growing (Patterson. 2018) with a new 
case of the disease appearing every 3 seconds. 
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For the sufferer, there are the aforementioned symptoms and their associated 
changes in quality of their life, but what is often ignored are the effects that this 
has on the immediate family and their community. Most new cases of dementia 
are being reported in low and middle-income countries, and in poorer countries 
familial care is often the only accessible option for those with the disease. 
Approximately 94% of those living with dementia in these countries are cared 
for at home, with a tremendous societal cost for the carers who are less able to 
commit time to work and broader societal contribution. (Prince et al., 2015) 
This presents as a further problem when countries become more developed. An 
increase in a country’s income is generally associated with increased 
participation in the workforce, often associated with an increase in women 
entering work. Combined with urbanisation and subsequent migration towards 
areas with more work, this all acts in concert to break down traditional 
extended family units in these countries. What this means for the dementia 
patient is that they have less accessibility for family care, forcing them to rely 
on a still primitive healthcare infrastructure not yet be suited to dealing with 
such an increased workload. (Prince et al., 2015) 
The increasing incidence of Alzheimer’s disease worldwide for national 
economies is causing financial strain as well as for the healthcare sector. The 
annual cost of dementia worldwide in 2014 placed the annual cost at 
approximately $600 billion USD, a year later in 2015 it was estimated that had 
risen to be around $818 billion USD, and by the latter half of 2018 to be close 
to $1 trillion USD worldwide. (Prince et al., 2015) (Patterson. 2018) 
With these statistics, Alzheimer’s disease should be one of the highest priority 
illnesses with regards to funding for research and care. However, the resource 
allocation of many countries for healthcare and research is often based off the 
Global Burden of Disease estimates by the World Health Organisation (WHO) 
and later by the Institute of Health Metrics and Evaluation (IMHE). These 
reports detail the burden of a disease, determined based on the overall levels of 
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disability it creates and the mortality rate. It then ranks them by their relative 
impact for the purposes of prioritising care. (Prince et al., 2015) 
The estimates given for these diseases are therefore heavily weighted towards 
those with higher mortality rates at an instant in time over those, such as 
Alzheimer’s disease, that have a rate of mortality that is spread out over time, 
despite the larger impact towards quality of life overall (Prince et al., 2015). 
Despite the aging worldwide population and inevitable upswing in incidence of 
Alzheimer’s disease, this disease seems to not be getting the resource allocation 
and healthcare priorities that are needed to develop long-term solutions and care 
strategies. This highlights the importance of the contribution of research to 
suggest innovative and preventative or ameliorating strategies that make 
Alzheimer’s disease easier for the affected individual and less of a burden to 
societies. 
 
1.3.1 Amyloid Beta aggregation 
 
How might focus on particular research strategies help this dilemma? As 
previously mentioned, the purported main mechanism underlying the 
development of Alzheimer’s disease is the aggregation of naturally-occurring 
Aβ in the brain, which then causes a variety of downstream effects culminating 
in the long-term disruption of normal brain activity and development of 
dementia. 
Aβ in its monomeric form has proven to be neuroprotective and healthy when 
operating within its physiological context and capacity. It is when Aβ begins to 
accumulate in the cerebrospinal fluid up to an approximate concentration of 
3μM that the neurotoxic dimers and higher-order oligomeric species begin to 
form (Nag et al., 2011). 
Once higher-order oligomeric species form, they are able to bind with cell 
membranes due to the exposed hydrophobic domains present on the oligomeric 
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complexes (Selkoe, 2011). This, in turn eventually leads to the characteristic 
amyloid plaques. It has been shown that these insoluble plaques exist in an 
equilibrium state whereby they allow the dissolution of oligomeric species from 
the body of the plaque and it is these dimers, trimers and oligomers that further 
bind to other cellular membranes and disrupt cellular function (Selkoe, 2011). 
These oligomeric species have been shown in mouse models to disrupt long 
term potentiation (LTP), the best available model of mammalian memory, act to 
enhance long term depression (LDP) and decrease both the number and the 
function of synapses (Selkoe and Hardy, 2016) (Shankar et al., 2008). 
 
1.3.2 Tau and Alzheimer’s Disease 
 
Tau in contrast to the proteins and peptides mentioned previously, has very 
little to do with the APP gene and subsequent processing pathways, however it 
does have a part to play in the neurophysiology of Alzheimer’s disease. In 
normal physiological conditions Tau is a polypeptide known to be essential for 
mediating the stabilization of microtubules in the cytoplasm. Tau is especially 
abundant in the central nervous system and usually is produced as an alternate 
splicing product of a gene known as microtubule-associated protein tau 
(MAPT) (Weingarten et al., 1975) (Goedert et al., 1989). In the pathogenesis of 
Alzheimer’s disease, Tau becomes hyperphosphorylated with disordered 
assembly into tangles of paired helical and straight filaments, the so-called 
neurofibrillary tangles that are one of the post-mortem hallmarks of 
Alzheimer’s disease (Goedert et al., 1988) (Alonso et al., 2001). Originally, this 
mechanism was thought to be self-mediated solely by tau from the 
consequences of the hyperphosphorylation, however more recently it has been 
found that Aβ may have a ‘prion-like effect’ on tau that causes it to convert into 
this state. In the absence of other proteins, it has been found that Aβ is able to 
bind to tau and induce an oligomeric state, which may suggest a possible 
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pathogenic mechanism for the development at least in part of some of the 
effects of Alzheimer’s disease (Nussbaum, Seward and Bloom, 2013). 
In mouse models of Alzheimer’s disease, however, there appears to be little 
link between Aβ deposits and the development of tau neurofibrillary tangles. 
More recent models using human neural stem cell derived cell lines in culture 
have shown more of a correlation. When mutations were introduced into the 
APP gene that mimicked familial Alzheimer’s disease: K670N/M671L 
(Swedish) and V717I (London) familial Alzheimer’s disease (FAD) mutations 
and/or PSEN1 with ΔE9 FAD mutation (PSEN1(ΔE9)) increased the amount of 
Aβ produced by the system and resulted in extracellular deposits of Aβ similar 
to those in the Alzheimer’s disease pathology. It was also observed that those 
neuronal cells with the familial Alzheimer’s disease mutations present also 
exhibited large levels of stably-aggregated phosphorylated tau fibrils 
intracellularly (Choi et al., 2014). 
Once it forms into neurofibrillary tangles, tau disrupts a number of intracellular 
functions and is currently thought to contribute significantly to the later stages 
of Alzheimer’s disease symptoms. With this cause and effect relationship in 
Alzheimer’s disease, the importance of preventative therapies and early 
intervention in the amyloidal accumulation stage cannot be overstated and 
ideally will be the focus of the majority of research until suitable treatments can 
be found. 
 
1.3.3 Neuroprotection by sAPPα 
 
It has been theorised that due to the shared amino acid sequence between the 
last 16 amino acids of sAPPα and the first 16 amino acids of Aβ that there is 
potential for binding to take place between these two proteins. Previous work 
from the Tate laboratory has shown that these two proteins are able to bind in 
vitro dependent upon their common sequence in a homomeric interaction 
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(Thomsen, 2012). Using glutathione sepharose beads, a pull-down assay was 
performed to determine if binding was taking place in vitro by the co-elution of 
GST- sAPP variants and Aβ from the column. It was found that GST-sAPPα 
interacted strongly with Aβ, evidenced by a large co-elution of Aβ from the 
column with GST-sAPPα. Comparatively a much lower amount of Aβ was 
found to co-elute with GST-sAPPβ, suggesting that the C-terminal 16mer 
sequence found in sAPPα plays a large role in binding with Aβ as sAPPβ lacks 
this sequence. Some secondary method of binding may occur as sAPPβ was 
still able to bind a smaller amount of Aβ. (Thomsen, 2012) 
A number of GST- sAPPα variants were used to investigate the domains that 
affected binding with Aβ. It was found that disruption or deletion of the heparin 
binding domain found in the C-terminal 16mer sequence drastically reduced 
binding affinity with Aβ. Reduced binding ability was also shown with clones 
that had the terminal lysine deleted or substituted with alanine or valine. This 
apparent reliance on the homologous sequence shared by Aβ and sAPPα was 
further proven by the inability of GST-sAPPα to bind with Aβ17-42, while still 
showing co-elution with Aβ1-16. (Thomsen, 2012) 
Potentially this could mean that there could be an ameliorating neuroprotective 
pathway enhanced if sAPPα concentration is increased in the right cell 
compartment whereby excess Aβ could be sequestered, preventing aggregation 
or allowing it to be cleared out of the brain therefore reducing the chances of 
Aβ accumulation.  
Not yet characterised, however, is which aggregation state of Aβ interacts with 
sAPPα. This knowledge is important if sAPPα were to be developed for use as 
a therapeutic for early stage Alzheimer’s disease, a strategy having previously 
been used by the research team successfully to that effect in mouse models (Tan 
et al., 2015). As it appears that aggregates are only able to form at a specific 
level of Aβ accumulation (a concentration of 3μM in the cerebrospinal fluid) 
(Nag et al., 2011), it would mean that any potential therapies developed using 
sAPPα would need to be administered at a very early stage in the disease before 
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there was any long-term damage. Potentially in the later stages of the disease, 
this binding mechanism between sAPPα and species of Aβ could act to reduce 
the soluble species of Aβ and therefore reduce the size of the insoluble plaques 
of Aβ by drawing more and more of the soluble oligomers out of their insoluble 
state by affecting the equilibrium of their association and dissociation with the 
insoluble plaque “reservoirs” (Selkoe, 2011). This approach would not mitigate 
damage already done by the development of the disease, only help to prevent 
further damage by these accumulated proteins, but it should be acknowledged it 
might have unanticipated negative effects by increasing the concentration of the 
more soluble species over the potentially ‘safer’ states sequestered in their 
insoluble form within the plaques.  
More recently, an indicator that sAPPα levels might be natural counter to the 
toxic effects of Aβ, was suggested from the observation that regulation of 
sAPPα expression has been linked to increasing Aβ presence in the brain. When 
Aβ was added to cell culture and mouse brain model systems, sAPPα 
expression increased in response. These data suggest a neuroprotective link 
between these two proteins and further emphasises the importance of 
characterising what Aβ aggregation states sAPP is recognising to determine if a 
therapy can be exploited from this process. (Rose, et al., 2018). 
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1.4 Research Aims 
 
The purpose of the work in this thesis, as a part of a much greater overall 
project with the eventual aims of better understanding Alzheimer’s disease and 
investigating the potential for development of therapies to manage and treat 
Alzheimer’s disease, was to better characterise how sAPPα interacts with Aβ 
and hence where it might be acting physiologically. It is clear from previous 
studies that there is an interaction between sAPPα and Aβ based on their 
common sequence and it is the specific goal of this study to attempt to further 
characterise this interaction in the context of the neural environment of 
Alzheimer’s disease. 
 
To that effect, the aims of this study were as follows: 
1) To produce recombinant GST-sAPPα and GST-sAPPβ fusion proteins 
in bacteria and purify the proteins on affinity columns based on the GST 
tag. 
2) To confirm the reported interaction between sAPPα and Aβ by MSc 
student, Maj Schneider Thomsen, using the column-binding method and 
thereby show the validity of this study. 
3) To separate species of Aβ based on size, with a size exclusion column 
and FPLC chromatography so that their binding behaviours might be 
investigated. 
4) To develop a simple assay method by which this binding could be tested 










All experiments were conducted under ERMA approvals GMD101715, 
GMD101717 and GMD101730. 
GMD101715: Approval for routine cloning in E. coli lab strains. 
GMD101717: Approval for protein over-expression in E. coli lab strains 
GMD101730: Approval for transient transfection of mammalian, plant and  
  insect cells and cell lines. Human cell culture approved in a class 
  II biological safety cabinet. 
 
 




2.1 Production and purification of sAPP variants 
 
2.1.1 Production of inducible GST-sAPP~ variant colonies 
 
Plasmid DNA (20ng) containing the sAPP variant of interest was added to 
1.5mL Eppendorf tube along with 200μl of BL21 Escherichia coli (E. coli) 
stock (BL21 cells were kindly supplied by Tina Edgar). A control tube was also 
assembled with equivalent ddH2O in place of the plasmid DNA. 
Tubes were subjected to a standard heat-shock protocol: following addition of 
DNA and ddH2O to each tube respectively, tubes were left on ice for 30 min. 
Heat shock was performed at 42°C for 45s and then tubes were cooled on ice 
for at least 5 min prior to the next step. 
 
2YT media (900µl) was added to both tubes and each were incubated for 45 
min at 37°C with shaking (200 rpm, 1-inch stroke length). From each tube 
100µl was plated onto LB+Amp+Chl agar plates, which were then incubated 
overnight at 37°C. The control plate was checked for no growth as the bacteria 
were antibiotic sensitive. Five antibiotic resistant colonies were selected from 
the ‘DNA’ plate –appearance indicated plasmid DNA had been taken up by 
these colonies and they were numbered 1-5. A new LB+Amp+Chl plate was 
divided into five equal zones and selected colonies were streaked out into their 
numbered zone for growth on the new plate, which was then incubated 





2.1.2 Small-scale induction tests of GST-sAPP~ variant colonies 
 
A sample from the streak of each sAPP-variant colony was collected with a 
toothpick and added to a 1.5mL Eppendorf tube containing 1mL LB, 100μg 
ampicillin and 30μg chloramphenicol. Tubes were incubated overnight at 37°C 
with shaking (200 rpm, 1-inch stroke length). 
These tubes were added to separate universal bottles containing 9mL LB, 1mg 
ampicillin, 300μg chloramphenicol for a total volume of 10mL. Universal 
bottles were incubated at 37°C with shaking (200 rpm, 1-inch stroke length) 
and OD600 was measured periodically until OD600 increased to 0.4-0.6. From 
each universal, 1mL was taken as a ‘pre-induction’ sample, the OD600 was 
noted and the samples were kept for further analysis. IPTG was added to a final 
concentration of 0.1mM and universal bottles were incubated for a further 4 h. 
From each universal, 1mL was taken as a ‘post-induction’ sample, the OD600 
was noted and the samples were kept for further analysis. 
 
Pre- and post-induction samples were centrifuged at 13,000rpm in new 
Eppendorf tubes for 15 min and the supernatant was discarded. SDSPAGE 
cracking buffer was then added to each sample in amounts based on the OD600 
of the sample that was noted originally: For each 0.01 OD600, 1µl of cracking 
buffer added – for example, a sample with 0.486 OD600 would have 48.6µl of 
cracking buffer added. Samples were then vortexed until fully mixed and heated 
at 96°C for 5 min. These samples were then suitable for loading onto an SDS 
PAGE gel to analyse the level of expression of the protein of interest within the 
five colonies, between the pre- and post-induction samples. The colony with the 




2.1.3 Large-scale inductions of GST-
sAPP~ colonies 
 
Following analysis by SDS-PAGE, the 
most-suitable colony for production of 
the sAPP was transferred via toothpick 
to a universal containing 10mL of LB, 
1mg ampicillin and 300μg chloramphenicol which was then incubated 
overnight at 37°C with shaking (200 rpm, 1-inch stroke length). 
The 10mL culture was then used to seed a large-scale culture of 500mL LB, 
50mg ampicillin and 15mg chloramphenicol in a baffled Erlenmeyer flask. This 
flask was incubated at 37°C with shaking (200 rpm, 1-inch stroke length) and 
OD600 was measured periodically until OD600 ≈ 0.4-0.6. 
A sample of 1mL was taken from the flask as a ‘pre-induction’ sample and 
IPTG was added to the flask to a final concentration of 0.1mM IPTG. The flask 
was then incubated in one of three conditions (Table 2.1). Following 
incubation, 1mL was taken from the flask as a ‘post-induction’ sample, both 
pre- and post-induction samples were centrifuged and analysed via SDS-PAGE 
gel as per section 2.1.2. 
 
2.1.4 Cell lysis 
 
Large-scale cultures were centrifuged in a 250ml Nalgene centrifuge bottle at 
13, 000g for 15 min. Supernatant was decanted and discarded whereupon more 
culture was added to the same bottle and re-centrifuged. Pellets were processed 
differently according to the lysis protocol being used. 
 
Table 2.1: Three conditions used for incubation of 
large-scale cultures and their associated 
timeframes. Longer times were used for the lower 
temperatures to allow for slower microbial activity. 








Pellets were resuspended in 5ml 1xPBS and then transferred to 15ml Falcon 
tubes. The bacterial suspensions were then sonicated at 30% frequency, 8×10 s 
each, with breaks of 30s between each sonication– during this time bacteria 
were cooled over ice. The degree of sonication was measured via absorbance at 
600nm. Un-sonicated suspension (20μl) was diluted 50 times to a final volume 
of 1ml and absorbance was taken relative to stock 1xPBS. This absorbance was 
then compared to a 20μl sample of post-sonicated material prepared in the same 
way. Ideally if the absorbance of the post-sonication sample was approximately 
1/100th of the pre-sonicated sample, it was assumed that efficient sonication and 
thus lysis of the cells had taken place. The post-sonication material was then 
centrifuged at 13,000g for 15 min and the supernatant was collected to 




Prior to grinding, a ceramicware mortar and pestle was sterilized by baking at 
200°C for 4h. Once the mortar and pestle had cooled to room temperature they 
were placed in ice for at least 30mins to cool. The pellet was then added along 
with an approximately equal amount of alumina and ground in the mortar and 
pestle for 30mins. The resultant paste was then resuspended in 5ml of ice-cold 
PBS and centrifuged at 13,000g. The supernatant consisting of the cell lysate 





2.1.5 Purification of GST-sAPP~ products (Lysate processing) 
 
1.5ml of preswollen glutathione-Sepharose beads were added to a 15ml Falcon 
tube and equilibrated for binding using 5ml of 1xPBS which was added to the 
beads and left for 15 min of turning end over end. The beads were then 
centrifuged at 500g for 5 min at 4°C to allow the removal of PBS. This was 
repeated twice more. 
A 5ml sample of cell lysate was then added to the beads and the tubes were 
incubated overnight at 4°C with end-over-end turning to allow GST fusion 
proteins to bind to the glutathione affinity moiety. 
The tubes were then centrifuged at 500g for 5 mins at 4°C and the supernatant 
collected as a ‘flow-through’ fraction. The beads were then washed with 5ml 
1xPBS for 5mins with end-over-end turning. The tubes were then centrifuged at 
500g for 5 min at 4°C and this supernatant was collected as ‘wash 1’. This was 
then repeated twice more for a total of three washes. 
Beads were then incubated with 0.75ml of elution buffer for 10 min, followed 
by centrifugation at 500g for 5 min at 4°C. The eluent was then collected for 
the ‘elution 1’ fraction. This was repeated twice more for a total of three 
elutions. 
 
2.1.6 Dialysis of purified GST-sAPP~ products 
 
Dialysis of GST-sAPP~ product was performed to exchange elution buffer with 
a binding buffer in and preparation for use in binding experiments. Dialysis 
used one of two methods (see below) both of which were found equally 
effective and thus deemed equivalent for the purposes of these experiments. 
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Following either dialysis method, samples were analysed via nanodrop against 
0.1PBS to determine their final concentration. 
 
2.1.6.1 “Classical” dialysis method 
 
Each dialysis used only half of the sample as a safety precaution and the other 
half was stored for dialysis at another time. 
Dialysis tubing was selected based on molecular weight cut off to be suitable 
for removing extraneous proteins: up to 12,000-14,000kDa; as GST-fusion 
proteins were all above this size. The tubing was soaked in ddH2O for at least 
30 min prior to use and all surfaces of the membrane were rinsed with 
additional ddH2O. 
The tubing was then clipped and the protein solution to be dialysed was added. 
Care was taken to ensure no air bubbles remained in the tubing and the other 
end of the tubing was clipped to ensure no leakage of protein. Solution was 
dialysed into 0.1 PBS and set to stir at a speed sufficient to cause a small 
amount of pull down of the membrane package. The volume of dialysis solution 
was 500ml and was changed after 4 h, the next morning again, and 4 h after 
that. The final dialysis was allowed to proceed for a further 4 h before the 
apparatus was dismantled and the dialysed protein solution was collected. 
 
2.1.6.2 Eppendorf-apparatus dialysis method 
 
Another method for dialysis was adapted from a literature reference (C.M. 
Overall, 1987) which had been found to be as effective for dialysis as the 
traditional method, however the chance of sample loss due to human error or 
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otherwise was drastically reduced and so this method became the preferred 
method for dialyzing the GST-fusion proteins. 
First, the wider end of a Pasteur pipette was heated over a moderate flame from 
a Bunsen burner. This was then applied to the lid of an Eppendorf tube, melting 
a hole in the centre of it. The ‘branding’ pipette and Eppendorf lid “core” were 
then removed and discarded, and the cored lid of the Eppendorf tube was 
removed and saved. Dialysis tubing was prepared as previous, by soaking in 
ddH2O for 30mins, however the dialysis tubing was then cut open to make a 
square sheet of single layered membrane for the use in this method. Eluent was 
halved as previous; to ensure safety of overall sample. One half was added to a 
new Eppendorf, whereupon the prepared membrane was placed over the top of 
the open tube and the tube was closed with the cored Eppendorf lid made 
previously – the original lid of the new Eppendorf was left open and attached so 
that the dialysed proteins need not be placed in a new tube after the dialysis and 
thus remove another chance at loss of product. 
The modified Eppendorf was then inverted and checked for leaks, before being 
placed inverted into a floating foam tube rack and placed into the dialysis 
solution, with care taken to ensure that no bubbles were allowed to remain 
between the surface of the modified Eppendorf lid and the dialysis membrane 
as well as all protein solution was in contact with the membrane and not 
adhering to the top of the tube. 
Dialysis was then performed as in section 2.1.6.1, with the same solution and 
timing. Once finished, excess dialysis liquid was blotted from the Eppendorf 
setup using a paper towel. The Eppendorf was then centrifuged down briefly to 
ensure all of the dialysed protein solution was at the bottom of the tube, the 
modified lid and dialysis membrane were then removed and the stock 




2.2 Production and purification of MBP-Aβ 
 
2.2.1 Induction of MBP-Aβ producing E. coli from established stocks 
 
Glycerol stocks of established Aβ-producing E. coli were collected and added 
to 5ml LB in a universal containing 100μg/ml Ampicillin to select for viable E. 
coli colonies. This was then incubated overnight at 37°C with a loosened lid 
and shaking (200 rpm, 1-inch stroke length).  
After overnight incubation, a large-scale culture flask was assembled, with 
500ml of LB with 100μg/ml Ampicillin and 10mM Glucose (0.22μm filter 
sterilised before adding to LB). This was then incubated at 37°C with shaking 
(200 rpm, 1-inch stroke length) until an OD600 of 0.4-0.6 was reached at 
approximately 4 h.  
Once the large-scale culture had reached the appropriate O.D of 0.4-0.6, a 1ml 
sample was taken to serve as a pre-induction sample for the sake of later 
comparison. This was then centrifuged at 13,000 rpm for 1 min to pellet cells 
and the supernatant was removed and discarded. To the pellet, the OD600 of the 
sample was multiplied by 100 to give an amount in microlitres of cracking 
buffer which was then added to the pellet and the pellet was resuspended; i.e. 
an OD600 of 0.59 would convert to 59μl of cracking buffer added. 
To the main culture, IPTG was added to a final concentration of 1mM and the 
culture was allowed to incubate at 37°C with shaking (200 rpm, 1-inch stroke 
length) for 4 h. After this time, the OD600 was measured and a 1ml sample was 
taken to serve as a post-induction sample that was processed in the same 




2.2.2 Extraction and purification of MBP-Aβ product 
 
Culture was transferred into a 250ml centrifuge flask and centrifuged in a 
JSP250 rotor at 4000xg, 4°C for 15 min. The supernatant was then discarded. 
Following this, the centrifuge bottle was refilled with more culture fluid and 
centrifuged again under the same conditions, with the supernatant likewise 
being discarded. Once all bacteria had been pelleted, the pellet was frozen at 
80°C overnight. 
Amylose resin (3ml) was added to a column and allowed to settle. This was 
then washed with 5 column volumes of 3ml each of affinity chromatography 
buffer, in total, 15ml. 
The bacterial pellet was then removed from the freezer and scraped into a 50ml 
falcon tube, this was kept on ice. Affinity chromatography buffer (10ml) was 
added and the pellet was resuspended. 
The bacteria was lysed by sonication at 20KHz, 20% amplitude 4x 30 s bursts. 
After lysis, the bacterial suspension was transferred to a round-bottomed 
centrifuge tube and centrifuged in a JA 20 rotor at 4°C, 17400g for 20min. The 
supernatant was kept as it contained the contents of the lysed cells, including 
the MBP-Aβ. A 5μl sample was reserved to later run on a gel. 
Affinity chromatography buffer was allowed to elute from the column until 
1cm of buffer remained atop the resin, to prevent the resin from drying out. 
Following this, the lysed cell contents were added to the top of the column and 
allowed to flow into the resin before the column tap was closed and the entire 
column was left to incubate at 4°C for 30mins. 
Non-bound proteins were then eluted from the column by adding 10 column 
volumes (30ml total) and allowing the buffer to flow through the column. The 
flow-through fraction was kept for further analysis and a 5μl sample was 
reserved to run later on a gel. 
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Bound proteins were then elute using 10 column volumes of elution buffer 
(30ml total) and this flow-through was likewise kept for further use, as well as 
taking a 5μl sample for a later gel run. 
The bound protein fraction was then concentrated via ammonium sulphate 
precipitation. Addition of ammonium sulphate was to 60% saturation, 
amounting to 0.392g added per ml of fraction. This was then stirred at 4°C for 
30min. The fraction was then transferred to a centrifuge bottle and spun at 
10,000g for 30min and the supernatant was discarded. The pellet, containing 
the protein was resuspended in 4ml of a low salt buffer (20mM Tris-HCL pH 
7.5) a 5μl sample was reserved to run later on a gel. 
The protein fraction was then desalted using a HiTrap® desalting column. This 
was run using 500μl of the protein fraction at a time. The protein was eluted 
into a low salt buffer (20mM Tris-HCL pH7.5) and fractions were pooled into 
5ml lots, these were frozen at -80°C overnight. The next day samples were 
freeze-dried and resuspended in factor Xa cleavage buffer to a final volume of 
50μl per ml of original pooled elute. The final protein concentration of the 
resuspended protein solution was determined via nanodrop- typically 10-
30mg/ml. 
 
2.3 Sepharose column experiments 
 
2.3.1 Preparation of non-stick Eppendorf tubes 
 
Tubes were prepared with a ‘silanised’ non-stick layer to prevent binding of Aβ 
non-specifically to walls of the tubes. This was achieved by treating previously 
autoclaved Eppendorf tubes with a 2% (v/v) solution of 3-
aminopropyltriethoxysilane for 15 min, ensuring all surfaces in the interior of 
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the tubes were covered. Following treatment with silane solution, tubes were 
rinsed with milliQ water and left to dry before being used in further 
experiments. 
Later this method was used to prepare tubes for all applications involving any 
tubes used to process or store Aβ to prevent loss of material. 
 
2.3.2 Binding experiments 
 
Pre-swollen glutathione beads (20μL) were used to test binding between GST-
fusion proteins and amyloid beta. First these were centrifuged at 500g for 5 min 
and the storage solution (50% v/v Ethanol) was removed. The beads were then 
equilibrated to binding conditions with 3 periods of 10 min at room temperature 
with 100μL PBS with end-over-end turning; at the end of each incubation 
period the beads were centrifuged at 500g for 5 min. The PBS was removed 
taking care not to remove any beads in the process, 100μL of PBS was then 
added, and the tube was gently vortexed for set up for the next equilibration 
repeat. 
Once the beads were ready for binding the PBS from the final equilibration step 
was removed as before and then 100μg of the GST-sAPP~ being tested was 
added. The tubes were then left to incubate at 4°C with end-over-end turning 
overnight. 
The next day, tubes were centrifuged at 500g for 5 min and the supernatant was 
collected as the column ‘flow-through’ -later checked for binding efficiency. 
The beads were then incubated 3 times with PBS exactly as before in order to 
wash away residual unbound protein as well as ensure optimal binding 
efficiency for the next step. The supernatant from each PBS wash was reserved 
for later analysis. 
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After the last incubation and removal of PBS, 2.25nM of Aβ in PBS was added 
to the beads (as this had been previously determined to be the optimal amount 
for binding) (Thomsen, 2012). The tubes were then left to incubate at 4°C with 
end-over-end turning overnight.  
The next morning, tubes were removed and centrifuged as before at 500g for 5 
min to allow removal of the Aβ ‘flow-through’ for later analysis. The beads 
were then washed as before with 3 incubations of PBS with end-over-end 
turning for 10 min each followed by centrifugation at 500g and removal and 
reservation of the supernatant for later analysis. 
The beads were then incubated 3 times with end-over-end turning and 20μL of 
elution buffer. Following each incubation period; the tubes were centrifuged at 
500g and the supernatant was collected – after which another 20μL of elution 
buffer was added and the next incubation began. After the final elution was 












2.4 PAGE and Western blot protocols 
 
2.4.1 native and SDS PAGE gels 
 
Separating Gel (Makes 2) 
 10% 12.5% 16% 
Separating gel buffer 
(4x) 




2.6ml 3.33ml 3.85ml 
H2O 3.4ml 2.59 2.07 
TEMED 6μl 6μl 6μl 
10% w/v APS 
solution 
75μl 75μl 75μl 
 
Stacking Gel (Makes 2-4) 
Stacking gel buffer (4x) 1.3ml 





10% w/v APS solution 22.5μl 
 
Gels were constructed using the Mini-PROTEAN® 3 system according to 
manufacturer’s instructions. First, the “separating” or “resolving” gel mixture 
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was made up and added to the gel system. This was then overlaid with 
approximately 1ml of isopropanol at room temperature to create a clean 
interface. The separating/resolving gel was then left to set for 30 min. When the 
gel had set, the isopropanol was washed away with water and the gel was 
drained. Any remaining water was blotted away with a paper towel, with care 
taken to ensure that no isopropanol remained in the gel cassette, nor any paper 
towel residue was left behind. After removal of the isopropanol, the stacking 
gel mixture was made up and added to the gel. The stacking gel was fitted with 
a 10 or 15 well comb depending on the application of the gel. The gel was then 
left again to set for 30 min. Upon setting, the gel was ready to use. If the gel 
were required to be stored the gel would be wrapped in wet paper towels and 
stored in an airtight plastic container at 4°C. Gels could safely be stored in this 
manner to a maximum of one week. 
SDS-PAGE gels were made to 10 or 16% w/v acrylamide depending on the 
application they were for which they were being used, i.e. for resolution of 
smaller proteins, the higher percentage gel would be used. Samples were 
prepared for loading on the gel by adding an appropriate amount of 3× cracking 
buffer, followed by thorough mixing. These samples were then heated at 96°C 
for 5 min, whereupon they were cooled to room temperature and loaded onto 
the gel. Samples were loaded next to a broad range molecular weight standard, 
so as to have a comparison for size purposes 
native-PAGE gels were exclusively made to 12.5% w/v acrylamide, as this was 
deemed appropriate for the resolution of a variety of Aβ aggregates. Samples to 
be loaded onto a native gel were added to an appropriate volume of 6× native-
PAGE loading buffer and were mixed thoroughly. The samples were then left at 
room temperature for 5 min, whereupon they were ready to be loaded onto the 
gel. As broad range molecular weight standards did not resolve properly in a 
non-dissociating gel, generally samples were compared to an appropriately 
concentrated sample of stock Aβ solution, which showed the full range of 
applicable aggregate forms possible in solution. 
35 
 
2.4.2 Western Blot 
 
Following the standard western blot protocol, two sponges and four sheets of 
pre-cut filter paper were soaked in transfer buffer. If using PVDF membrane, 
this was activated by soaking in methanol for 30 s, followed by a brief rinse in 
water and finally a 2 min soak in transfer buffer. If using nitrocellulose 
membrane, this was washed in transfer buffer for 2 min prior to use. 
The western blot cassette was then assembled from the negative electrode to the 
positive: sponge, two sheets of Whatman paper, gel, nitrocellulose or PVDF 
membrane, two sheets of Whatman paper, sponge. This was then run at 28V for 
60 min to transfer with an ice block in the Western tank and stirring to keep the 
temperature of the buffer consistent. 
The cassette was then disassembled and the membrane removed, with care 
taken to keep the side that had been transferred onto face up. If the gel had 
contained a protein ladder, the membrane was then soaked in methanol for a 
brief period, followed by a 5min incubation with rocking in Ponceau red stain. 
The membrane was then transferred back into methanol and shaken lightly until 
the bands in the protein ladder were visible on the membrane – these were then 
marked lightly with pencil to allow easy visual identification later. 
The membrane was then incubated with 1% w/v milk powder in TBS-tween 
overnight at 4°C with gentle rocking. The next morning, the membrane was 
transferred into 1% w/v milk powder in TBS-tween with an appropriate 
concentration of the primary antibody – this was incubated for 2 h with gentle 
rocking at room temperature. The membrane was then washed 3x with 10 min 
incubations in TBS-tween with gentle rocking, followed by transferral into 1% 
w/v milk powder in TBS-tween with a 1:10, 000 concentration of the secondary 




The membrane was then washed a further 3 times as before and developed 




Freshly-run gels were transferred into Coomassie stain for 2 h, followed by a 1 
h incubation in de-staining solution. This was followed by incubation in milliQ, 
which was changed periodically until the gels had a clear background. 
 
2.4.4 Colloidal Coomassie 
 
Freshly-run gels were transferred from the apparatus into containers – milliQ 
water was then added to cover the gels and they were incubated 15 min with 
rocking to remove residual SDS. The water was then removed. 
The colloidal Coomassie stain was shaken to resuspend its contents before 
being added to the gels and incubated with rocking overnight. 
The next day, stain was removed and recanted back into its bottle. The gels 
were then incubated with milliQ water with rocking. The water was changed 
periodically and gels were incubated until they had a clear background. 






2.4.5 Zinc Staining 
 
Occasionally gels would have to be viewed with a reversible stain in order to 
best position the membrane for Western blot experiments or to mark the 
membrane to show the location of the transferred lanes. 
Staining: 
First, an SDS gel would be incubated in water for 30 min, in order to wash 
away excess SDS. A native/non-dissociating gel contained no SDS and 
therefore would not need this step. 
The gel was incubated in 0.2M Imidazole for 10 min at room temperature with 
rocking. The stain was checked every few min by placing the gel container over 
a dark background. 
Once bands were visible in the gel, it rinsed briefly in ddH2O and scanned. 
De-staining: 
The gel was then placed in a 2% w/v citric acid solution to reverse the stain. It 
was incubated for 5-10 min depending on the time it took for the stain to 
disperse. 
The citric acid solution was changed every 2.5 min during the de-staining 
process. 




2.5 Aggregate work  
 
2.5.1 Initial aggregation/disaggregation tests 
 
Small scale aggregation tests were performed in order to determine a reliable 
method for generating them to use in later experiments. Following a method 
used by Cerf et al (2009), lyophilised Aβ was dissolved at a 1mg/ml 
concentration into sterile 1xTBS. A 90μl sample was taken and diluted with 
110μl of sterile 1xTBS to a final concentration of 100μM – this was then 
incubated at 4°C for 24 h with no agitation. The final product was then loaded 
onto a native/non-dissociating PAGE gel to visualise formed aggregates and 
compare with the non-aggregated material from the original sample. Upon 
staining the gel, it was found that this step was entirely unnecessary as 
aggregates formed readily in 1xTBS within a few minutes of Aβ being 
dissolved. 
Aβ in 1xTBS (200ul of 1mg/ml) was then taken in order to test a disaggregation 
protocol developed by K.Bhaskar et al (2009) and used frequently by Tate lab 
PhD student Katie Peppercorn to generate monomeric samples. The sample was 
centrifuged at 13,000prm for 5 min in order to pellet out the insoluble 
aggregates formed as part of the dissolving process. The supernatant was then 
removed and saved for later experiments. The pellet then had 200μl of 10mM 
Sodium Hydroxide pH 10.5 added and it was vortexed to mix as much as 
visually possible. The tube was then sonicated for 10 min in 10 s bursts at 30% 
amplitude with 30 s interludes on ice between sonications. The tube was then 
centrifuged at 13,000 rpm in a benchtop centrifuge for 30 s, to check that there 
was no pellet, indicating successful disaggregation – whereupon 800μl of cold 
0.1M sodium phosphate buffer pH 7.4 was added and tube was vortexed to mix. 
A sample of the final product was then run on a native/non-dissociating PAGE 
gel to compare generated monomers with the stock material. 
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2.5.2 Centrifugation separation of aggregates 
 
A Method was adapted from Esparza et al 2016 with some changes to account 
for the fact that the samples used were derived from a pure preparation of Aβ 
(lyophilised) and not derived from human brain homogenate. 
Aβ (1mg) was dissolved to a final concentration of 1mg/ml in 1xTBS with 
moderate vortexing and left at room temperature for 10 min to encourage 
formation of a variety of aggregates. 
Following this, 0.5ml of Aβ solution was centrifuged at 100,000g for 1 h to 
pellet out insoluble higher order aggregates. The supernatant was then 
transferred to a separate tube and a 0.5ml 70% w/v sucrose cushion was gently 
underlaid below the Aβ with the use of a syringe – in order to maximise 
recovery of material post-centrifugation. The tube was then spun at 475, 000g 
for 1 h. 
Samples (each 100μl) were taken in layers starting from the top of the tube and 
working downwards –with an aim of sampling each aggregate form from 
lightest to heaviest. These samples were then run on a native PAGE along with 
unfractionated Aβ to compare. 
 
2.5.3 Column separation of aggregates 
 
To prepare a more exact set of different aggregates, size exclusion 
chromatography was used with the buffer conditions of Esparza et al 2016; 
where elution with 150mM NH4OH preserved aggregate forms.  This was 
compatible with the Superdex 75 10/300GW 3,000-70,000mw chromatography 
column. Fractions (250μl) were generated from the column and the peaks of 
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interest were selected to be investigated in further experiments. 
 
2.5.4 BCA assay of column separated samples 
 
In order to determine the concentration of protein in Aβ-containing fractions 
eluted from the size-exclusion column, a modified version of a BCA assay was 
used. A modified protocol is required due to the single tyrosine and lack of 
tryptophan in Aβ. 
First, working solution was prepared. Each well required 200μl of working 
solution and including three blank wells, the eight samples and six protein 
standards in triplicate, the final number of wells used was 29. A 50:1 mixture of 
BCA buffer and Cu2+ solution was required for the assay, to mitigate errors, 6ml 
of buffer was added to 120μl of Cu2+ solution in order to produce enough 
working solution to accommodate slightly over 30 wells. 
A serial dilution of Aβ was used as a standard, so as to estimate the 
concentration of the Aβ fractions from a matching absorbance. First a solution 
of 1mg/ml Aβ in TBS was diluted to 0.25mg/ml in NH4OH, this served as the 
first control. Each subsequent control was diluted to half concentration in 
NH4OH until five controls were made in total. The sixth control was purely 
NH4OH and also served as a blank for the purposes of the assay. 
Each sample (25μl), controls and blank, were pipetted into their own wells of a 
96-well assay plate, to which 200μl of working solution was added to each 
filled well. This assay plate was then incubated for 30 min at 60°C. Running 
this assay at 60°C, allows the reaction to detect peptide bonds rather than 
relying of tyrosine and tryptophan, making it more suitable for analysing the 
concentration of Aβ. 
Once the assay incubation was complete, the absorbance of the wells was 




2.6 Membrane binding experiments 
 
2.6.1 Western blot binding protocol 
 
Method adapted from Ueki et al 2011 
GST-sAPPα (1μg) was loaded into 6 lanes (with alternate lanes left empty for 
spacing reasons) of a standard 10% w/v SDS gel and ran at 200v for 1h. 
Following this, the gel was soaked in transfer buffer for 20 min at room 
temperature with gentle rocking. 
The gel was then electro-transferred onto nitrocellulose membrane following 
the standard Western blot protocol. The membrane was then carefully marked 
to show the positions of each of the GST-sAPPα lanes in the nitrocellulose 
membrane. 
Following electro-transfer; the membrane was incubated for 15 min in 15ml of 
Buffer A (30mM Tris-HCL pH 7.4, 0.05% v/v Tween 20) with gentle rocking. 
The nitrocellulose-bound proteins were then refolded to best ensure binding 
capacity, the membrane was transferred to 25ml of denaturation buffer (7M 
guanidine hydrochloride, 2mM EDTA, 50mM DTT, 50mM Tris-HCL pH 8.3) 
and incubated for 2 h with gentle rocking at room temperature. The membrane 
was then washed with 25ml TBS for 5 min with gentle rocking and then 
transferred into 25ml of binding buffer (140mM NaCl, 10mM Tris-HCL pH 
7.4, 2mM EDTA, 2mM DTT, 1% w/v BSA, 0.1% v/v Tween 20) with gentle 
rocking at 4°C overnight. 
The membrane was then cut into strips, following the markings made earlier to 
ensure one strip contained one lane’s worth of GST-sAPPα. The membranes 
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were then incubated in hybridisation solutions containing 2μg of each aggregate 
form in fresh binding buffer for 1.5h with gentle rocking. 
The membranes were then washed three times in 600μl TBS and blocked 
overnight in 600μl 1% milk powder TBS overnight. The membranes were then 
probed as standard with 6e10 Mouse anti_1-16 Aβ. 
 
2.6.2 Dot blot binding protocol 
 
Firstly, 4μl of GST-sAPPα solution was blotted in several spots onto cellulose 
membrane and allowed to dry, this was slowly pipetted onto the membrane in 
order to keep the dot as small an area as possible for the purposes of later 
analysis. The membrane was then cut into strips, such that each dot of protein 
was on an individual strip of membrane – these membrane strips were then 
rolled as such that they were able to be placed into a 1.5mL Eppendorf tube 
without any overlap between areas of the membrane. The membranes were then 
washed overnight with end-over-end turning in 600μl of 1% w/v milk powder 
TBS-tween to block non-specific binding. Following this; membranes are each 
washed with 2μg of specific aggregate forms of Aβ in 600μl of 1% w/v milk 
powder TBS-tween via end over end turning overnight in order to facilitate 
binding between Aβ aggregates and GST-sAPPα anchored on the membrane. 
 
Following the overnight binding step, membranes were each washed 3 times in 
TBS with 15 min incubations with end-over-end turning per wash. The 
membranes were then blocked in 600μl 1% w/v milk powder TBS-tween for 
1h, with end-over-end turning. Following this, the standard Western blotting 
protocol was used, with a 2h incubation with the primary antibody – 6e10 
Mouse anti_1-16 Aβ that is specific for both of the proteins used in the binding 
assay. Next, three 600μl washes in TBS-tween were carried out with end over 
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end turning and a 15 min incubation per wash, followed by a 1h incubation with 
the secondary HRP-Rabbit-anti_mouse antibody and then another 3 600μl 
washes in TBS-tween as before. Finally, membranes were developed with HRP 
solutions and visualised with chemiluminescence. 
 
2.6.3 ImageJ analysis 
 
To better show the relative fluorescence of the dot blot binding tests and 
therefore have some measure of confidence that a comparison could accurately 
be made between relative binding levels – a method was adapted from 
“Quantifications of Western Blots with ImageJ” (H. Davarinejad).  
As a method to reduce background effects and therefore get a clearer result a 
“Negative” dot blot was produced, where GST-sAPPα was blotted onto the 
membrane and was treated in the same manner as the binding blots, with the 
absence of any exposure to Aβ. This was used in the method as a replacement 





3.1 Expression and purification of GST-sAPPs 
 
The first stage of the project was to produce sAPP protein with a GST affinity 
tag that would be used both for purification of these proteins but also as a 
demonstrating an interaction between the sAPP proteins and Aβ and its 
aggregates. First, conditions were determined that gave the optimal GST-sAPPs 
production as shown in Figure 3.1. 
 
3.1.1 Small scale inductions of E. coli pGEX GST-sAPPα 
Fig. 3.1: Small scale induction tests of individual GST-sAPPα-producing 
colonies of E. coli. Cell extracts of individual colonies of E. coli expressing 
GST-sAPPα were compared for their expression levels for selection of the best 
colony for large scale production. M – molecular weight marker proteins, lanes 
are separated into: i – initial pre-induction, f – final post-induction samples. 















Small-scale inductions of several E. coli pGEX colonies were used to test for 
those that best produced the inducible protein. As can be seen in Fig. 3.1; five 
colonies were selected from the plates of transformed bacteria and underwent a 
small-scale culture and induction test – on the gel the initial “i” (at induction 
time) and final “f” (after 4h of incubation) results have been loaded side by side 
for each colony. It can be seen that a band appears in the ‘final’ lanes of each 
colony that is not present in the ‘initial’ lanes. This is at the expected Mr of 
GST-sAPPs and demonstrated the inducibility of the protein GST-sAPPα.  
Colonies 2, 3 and 4 had the highest and equivalent amounts of GST-sAPPα 
protein present post-induction but clearly more overall protein was loaded on 
the gel for colony 4. Colony 3 was chosen to carry forward to the large-scale 
production of GST-sAPPα. 
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3.1.2 Investigation of optimal temperature conditions for production of 
GST-sAPPs 
Fig. 3.2: Comparison of expression and solubility of sAPPα at three 
different temperature conditions for E. coli growth. At each temperature 
(18°, 25°, and 37° cell extracts were separated into insoluble (I) and soluble (S) 
fractions (I and S in the figure). Molecular weight marker proteins are shown 
with relative masses in the left lane. Unmarked lanes are empty of protein to 
allow for better visual acuity.  
 
As shown in Fig.3.2 the ratio of insoluble GST sAPPα and soluble products 
varied with the temperature conditions. The best yield of soluble GST-sAPPα 
occurred at 25°C and 18°C. Future expression of GST-sAPPs were carried out 
18°C due to convenience. From a 500ml culture of colony 3 a cell extract was 



























3.1.3 Purification of GST-sAPPα on glutathione Sepharose 
Fig. 3.3: Affinity Purification of GST-sAPPα on glutathione-Sepharose. 
Lanes labelled as follows: M- protein standard marker, FT – flow-through from 
the column after incubation with cellular lysate fraction, W1-W4 – flow-
through from washing the column with PBS. E1-E4 – elution fractions from the 
column using elution buffer. 
 
The binding and elution of GST-sAPPα from the glutathione Sepharose column 
(Figure 3.3) showed a small amount of protein in the wash lanes and a protein 
of the expected size of GST-sAPPα in the first two elution fractions. However 
the flow-through (FT) from the load sample has significant amounts of GST –
sAPPα, suggesting only a small fraction has actually bound to the beads and the 
capacity of the column was exceeded. This fraction could be recycled through 
the column for greater recovery.  Non-specific protein was washed from the 






greatly reduced in wash 2 (W2) with an unexpected increase in protein with 
wash 3 (W3), to be nearly not visible protein in wash 4 (W4). The GST-sAPPα 
protein then is clearly seen in elution 1 (E1) and elution 2 (E2), but barely so in 
the two subsequent elutions; it appears that at least two elutions (elution buffer) 
are required to fully elute bound protein. 
 
3.1.4 Small scale inductions of GST-sAPPβ 
 
Fig. 3.4: Small scale induction tests of GST-sAPPβ-producing colonies of E. 
coli, SDS PAGE gel. Lanes: M – Broad range marker, Pre- pre-induction 
sample of colony 1, and post-induction samples from colonies 1-5  
 
Small scale inductions GST-sAPPβ-producing colonies of E. coli were 
performed to determine a good producer of the protein of interest. As can be 











Marker size (kDa) 
M   Pre    1      2      3     4      5 
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is shown as representative. The 5 samples at the +4h after induction time point 
were then loaded in series from 1-5. The gel in Fig. 3.4 shows that all colonies 
produced GST-sAPPβ in varying amounts after being induced – the lower end 
of production were colonies 2 and 3, with the best being colonies 1 and 5. The 
colony that produced the most GST-sAPPβ was colony 4 but had a higher 
loading of all proteins so these three colonies were deemed equivalent in their 
expression. 
 
3.1.5 Identifying GST-sAPPβ products 
 
During production and analysis of GST-sAPPβ, an unexpected band appeared 
on gels of production runs. It was suspected that this band had somehow been 
produced independently of sAPPβ but was of higher molecular weight than 
GST (27kDa). As shown when the GST- sAPPβ was purified on Glutathione 
columns this band eluted with added glutathione. This suggested it was being 






















Fig. 3.5: SDS-PAGE gel of five different GST-sAPPβ affinity column 
elutions. The unexpected band is outlined in red. 
 
 
Fig. 3.6: Western blot of the gel shown in Fig. 3.5. Blot was probed using 
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The band was detected with an anti-GST antibody (lower arrow) (Fig.3.6) as 
well more faintly the GST in GST-sAPPβ (top arrow) suggesting that GST had 
somehow either been expressed from a different translational initiation site or 
had been cleaved from the fusion protein by an unknown E. coli protease. In 
order to fully confirm the presence of GST in the band, a matrix-assisted laser 
desorption/ionization (MALDI) analysis was carried out. 
 
3.1.6 MALDI analysis of aberrant GST bands  
 
 
Fig 3.7: pBLAST search using sequence derived from MALDI analysis 
performed on suspected GST bands. 
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The MALDI analysis produced peptide sequences that gave 100% sequence 
match with the GST encoded in the pGEX-6P 3 vector. This confirmed the 
‘mystery band’ contained the GST sequence either translated from a different 
initiation site or was a cleavage product arising by an unknown protease. 
 
3.1.5 Production of Maltose Binding Protein -Amyloid Beta fusion 
protein (MBP-Aβ) 
 
Amyloid beta can be expressed in bacteria as a fusion protein with maltose 
binding protein and that stabilises the expression product. Expressed as the 
peptide alone results in rapid turnover of the expressed Aβ (Wilson, 2004) 
Fig. 3.8: Vector map of the pMAL c-2 vector showing structure and 
addition of Aβ gene. Diagram reused from Wilson, 2004. 
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The first stage of amyloid beta production was to use an MBP –Aβ expressing 
bacterial clone DH5alpha, available in the Tate laboratory. The expressed 
MBP-Aβ was purified on an amylose affinity column that bound the MBP as 
shown below. 
Fig. 3.9: Production of MBP-Aβ in E. coli. SDS PAGE of bacterial protein 
extracts after induction of expression of MBP-Aβ. Lanes labelled as follows: M 
– broad range marker, CL – cell lysate (post sonication sample), UB – unbound 
protein sample, BP – bound protein sample, PA – post ammonium sulphate 
precipitation. 
 
The expression was monitored after induction with IPTG with 4h being the 
optimum expression (not shown). As shown in Fig. 3.9 the cell lysate (CLS) 
had a large band at the expected molecular weight of ~45kDa. Then amylose 
affinity column was used to bind the MBP-Aβ and separate it away from the 
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flowing through the column (UB) and the highly purified MBP-Aβ is shown in 
the bound fraction (BP) are shown in Figure 3.9. The bound fraction was eluted 
with maltose and then concentrated by ammonium sulphate (PA). After taking 
up the precipitate in factor xa cleavage buffer (20 mM Tris·Cl, pH 6.5; 50 mM   
NaCl; 1 mM CaCl2), compatible for cleavage of the MBP from the complex, it 
was desalted by FPLC chromatography (see Figure 3.10).  
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Fig. 3.10: Desalting from MBP-Aβ production, clear sharp peaks are 
observable between protein and salt. A: Multiple desalting column repeats 
were performed on a HiTrap® desalting column by FPLC. The protein (shown 
in pink) was separated from the residual salt (brown). B: Expanded view of one 
separation in A. 
 
A nanodrop reading of the concentration of the final product after desalting by 
FPLC chromatography (Figure 3.10) showed that it was 9.35mg/ml with a yield 













































































































be needed for the subsequent studies, and since cost and quality of commercial 
Aβ had improved markedly, this preparation awaiting cleavage was reserved for 
critical later experiments. 
 
3.1.6 Can and interaction between GST-sAPPs and Aβ be detected? 
3.1.6.1 sAPPα and Aβ 
 
Binding was tested first between Aβ and sAPPα. The N terminal GST tag 
facilitated anchoring of sAPPαonto the glutathione Sepharose beads. After 
washing the column, Aβ was loaded onto the column in a second step. Elution 
patterns of the GST-sAPPα and Aβ could then be analysed for evidence 
supporting an interaction between the two molecules. The bound proteins were 









Fig. 3.11: Interaction of GST-sAPPα with AβSDS PAGE of fractions from 
a GST-sAPPα/Aβ interaction study showing markers, load fraction, unbound 
flow through fraction, all washes and elutions. M – Marker (Low molecular 
weight protein range), first step: SL - GST-sAPPα load, W1-W4 – post wash 
sample, second step: ABL – Aβ load, W1- W3 washes, E1-E2 – elution sample 
As can be seen in the last two lanes of the gel in Fig. 3.10, both proteins co-
eluted from the beads in the two elution fractions. There was also evidence of 
the GST band identified (Fig. 3.7) in the elution fractions (middle arrow) 
The experiment was repeated with a lower load of the GST-sAPPα containing 
fraction. A higher proportion bound to the column and the co elution can be 
clearly seen in fraction E1.  
A repeat interaction experiment is shown on Fig  3.12 with the successive loads 
of GST-sAPPα (SL) and Aβ (ABL) and the three elution fractions (wash 
fraction not shown). Here the Aβ appeared predominantly in the first fraction 















Fig. 3.12: Co-elution of sAPPα and Aβfrom glutathione-Sepharose. SL is 
GST-sAPPα load sample, ABL the Aβ load sample and E1-E3 the elution 
fractions  
Fig. 3.13: Western of the gel profile in Fig 3.11. Probed with specific 
antibody against Aβ17-42 (4G8Aβ) Labels are as Fig 3.11. 
 












Marker size (kDa) 
 M      SL    ABL    E1      E2      E3 
59 
 
The immunoblot (Figure 3.13) showed Aβ was co-eluting with GST-sAPPα in 
the E1 lane. The lower band reacts with the antibody specific for Aβwhereas 
the upper band in Figure 3.12 containing GST–sAPPα does not, so as not to 
detract from analysis of visible areas of this figure, the upper area has been 
omitted. A further point of note within Figure 3.13 is the presence of an 
additional ~14.5 kDa band that appears in the E1 lane that is not present in the 
Aβ load (ABL). It’s possible that this band is a result of aggregation in the Aβ 
from lower order species, but without further analysis any comments on its 
origins are purely speculative. It can be seen in both figures that a significant 
amount of material is being lost between the Aβ load and subsequent elutions, 
as the sum of the Aβ present in the elutions seems to be far lower than the total 
amount of Aβ present. Aβ is known to be a highly ‘sticky’ protein.  
From these data, it has been shown when GST-sAPPα is bound to a Sepharose 
column and then exposed to Aβ, these two proteins co-elute with free 
glutathione addition after all of the unbound protein is washed away. These data 
suggest that these proteins interact in-vitro and this may be a physiologically 











3.1.6.2 GST-sAPPβ and Aβ 
 
As with GST-sAPPα, binding experiments were performed using GST-sAPPβ 
and Aβ on a glutathione Sepharose column. These were then transferred onto 
PVDF membrane and probed using the 4G8 anti-Aβ antibody. 
Fig. 3.14: Western blot of elutions from glutathione Sepharose columns. 
After GST-sAPPβ and Aβ had been loaded successively to the glutathione-
Sepharose column, the column was washed and eluted with glutathione 
(10mM). Membrane was probed with 4G8 anti-Aβ17-42 antibody. M- Broad 
range marker. E1-3 – elution fractions from column. 
 
GST-sAPPβ likewise coeluted with Aβ, in at least two of the elution fractions; 
suggesting that it too is able to bind with Aβ in-vitro. Unfortunately, the 
Coomassie-stained gel of this experiment was unable to be visually resolved 











Marker size (kDa) 
 M     E1    E2    E3 
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3.1.7 Is the interaction of sAPPαand Aβ independent of GST? 
 
GST produced previously from the pGEX vector system was also used as a 
negative control for the binding in order to verify that binding was not taking 
place between GST and Aβ in the previous experiments and thus that their 
results were reliable. Previously, it has been determined that 20μg is the 
optimum GST amount for binding to this size of column (Thomsen, 2012). This 
load was therefore determined to be the ideal for comparison of binding 
activity.  
 
Fig. 3.15: Western blot of GST binding elutions compared with Aβ load 
fraction. ABL- Aβ load for comparison, E1-3 – elution fractions. Marker lane 
did not transfer properly and was unable to be annotated. 
 
Aβ did not bind to the column preloaded with GST and was not present in any 
of the elution fractions with GST (Fig.3.15). suggesting that GST is being 
eluted alone, and no Aβ remained on the column after the wash steps. This 
shows that the interaction of Aβ with sAPP is not through the GST tag placed 
 M     ABL   E1     E2     E3 
62 
 
on the two proteins suggesting that binding is taking place between the sAPP 
portion of the fusion protein and Aβ. Unfortunately, a Coomassie-stained gel 
was unable to be resolved in the timeframe of this study, however there is no 
current evidence in the literature to support the binding of Aβ to GST. 
 
3.2 Investigation of which forms of Aβ are interacting 
with sAPPs 
 
3.2.1 Initial tests of aggregation of Aβ with native-PAGE gels 
 
SDS-PAGE is commonly used in the literature to identify aggregate forms of 
Aβ. While this may be possible because the interactions in the aggregate forms 
are so strong it may also underestimate the aggregates in Aβpreparations.  
A native/non-dissociating gel protocol (Cerf et al., 2009) was used therefore to 
determine the types and abundance of aggregates in a sample of Aβ. 
Aggregation was promoted by dissolving Aβ as lyophilised powder at 1mg/ml 
in 1x TBS and leaving it for 24h at 4°C. This step later proved to be largely 
unnecessary as aggregates would readily form in solution and would largely 





Fig. 3.16: Aggregation of Aβ detected on non-dissociated gels. [A] An 
example from the literature (Cerf, et al., 2009) showing the distinct bands 
present in a sample of aggregated Aβ (Reused with permission) [B] Aggregated 
Aβ (24h at 4°) at 1mg/ml was fractionated on a 12.5% native PAGE gel and 
subjected to Western blotting, probing with 6e10 anti-Aβ1-16 antibody. 
Fig. 3.17: SDS gel run with the same sample of Aβ (1mg/ml left at 4°C for 
24h). This sample only shows one band on the SDS-PAGE gel, compared to the 











Hence aggregate forms are readily formed in solutions of Aβ, but visually 
identifying them is best done by a native PAGE gel as the dissociating SDS gel 
greatly affected the number of visible aggregate bands. 
 
3.2.2 Disaggregation tests with Aβ 
 
As Aβ rapidly aggregated in solution, methods were explored to facilitate the 
generation of monomeric species for use in further experiments as a comparison 
to its higher aggregate forms. 
Several methods to disaggregate Aβ were trialled, however none were 
particularly effective when the samples were analysed on native PAGE gels, 




Fig. 3.18: Western blot of a comparison between the product of a 
previously successful disaggregation protocol and non-disaggregated Aβ 
from a native page gel. The Aβforms were detected with 6e10 antibody. 
 
Attempts at disaggregation of Aβ samples only appeared to spread the majority 
of the Aβ from the monomeric form across the entire spectrum of Aβ aggregate 
forms (Fig 3.18). Potentially this meant that attempts at disaggregation actually 
served to increase aggregation, coupled with sample loss from either sticking to 
tubes or equipment such as the sonicator probe – previously using SDS gels 
would have masked this effect. These observations have implications on 
established results based on SDS gels to determine aggregation states of Aβ. 
 
Stock Aβ Treated Aβ 
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3.2.3 Separation of Aβ aggregate forms by centrifugation 
 
To test the individual binding characteristics of various forms of Aβ aggregates, 
samples of each form had to be produced – this was accomplished initially by 
centrifugation at high speed with a sucrose cushion to allow for better sample 
recovery (Esparza et al 2016). 
Following centrifugation, samples were run on a 12.5% native PAGE gel and 
transferred to PVDF membrane. This was then blotted with 6e10 antibody that 
is specific to Aβ1-16 the non-aggregating part of Aβ, that had previously been 
shown to react to the entire range of aggregates producible from Aβ. 
Fig. 3.19: Western blot of separated fractions of Aβafter centrifugation. 
Aggregates are outlined in red. Lanes: Stock Aβ (S), 1-5 from each layer 
removed from the centrifuge tube in order. The ‘insoluble’ fraction is not 
visible in this image – but was derived from the insoluble material removed by 
the first centrifuge spin at 180,000g. Blot produced from 12.5% native PAGE. 
 
Using the centrifugation protocol, it was possible to separate the aggregate 
forms into distinct fractions for use in later experiments (Fig. 3.19). Sample 1 
S         B          1        2       3        4        5 
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was designated as the monomeric sample as that appears to be the only species 
present (although all fractions contained monomeric species). Samples 2 and 3 
were designated the dimer/trimer samples as these species became more 
prevalent in these fractions. Sample 2 was used preferably as it had a small 
amount of higher oligomers. Samples 4 and 5 were designated the oligomeric 
samples – Sample 5 was used preferentially as it was slightly richer in 
oligomeric species. 
 
3.2.4 Interaction of different aggregation states of Aβwith sAPPα 
 
In an attempt to reduce the opportunity for further aggregate formation in the 
centrifugally separated fractions, a binding protocol was utilised that would 
enable anchoring of one component onto a membrane where binding could be 
tested safely without any change in its aggregate state. 
Fig. 3.20: An attempt at Western blotting binding protocol. Positive control 
(+) which contained unfractionated Aβ. Strips labelled with the aggregation 
state of Aβ that they contained: M – monomer, D/T – dimer/trimer, O – 
oligomer, I – insoluble. 
 
  +          M           D/T        O          I 
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Given, the disappointing results with immobilising Aβ aggregates, and probing 
with GST-sAPPα, the GST sAPPα was transferred to the membrane and 
immobilised and the individual Aβ aggregates were used as the probes. As seen 
in Fig 3.20 an ugly blot resulted but there was a hint of binding by the monomer 
(M lane) but again the blot was ‘plagued’ with background problems. 
Fig. 3.21: Western binding protocol with GST-sAPPα immobilised. The 
protocol was reversed from Fig 3.19 in that in this experiment GST-sAPPα was 
bound to the membrane, whereas the aggregate forms of Aβ were the ‘prey’.  
 
Based on these results however (Figures 3.20-3.21) this method was deemed 
unsuitable although in both experiments, the monomeric species appeared to 
react the most to the antibody – suggesting interaction had taken place. 
However, the results and chemiluminescent patterns were too unpredictable and 
not reproducible to draw conclusions from. 
A new method using immobilised GST –sAPPα was investigated.  
  +              M             D/T            O     
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3.2.5 Dot blot to measure interaction between specific aggregated 
species of Aβ and GST-sAPPα 
 
Analysis of binding results of preliminary experiments suggested that the 
oligomeric sample displayed the highest level of binding with the anchored 
GST-sAPPα. A typical dot blot is shown in Fig 3.22, with the analysis in table 
3.1. 
 
Fig. 3.22: Development of a dot-blot binding protocol. The membranes were 
probed with 6e10 anybody specific for Aβ1-16–that allowed both detection of the 
immobilised GST-sAPPα and, from enhancement of the signal, the interaction 
of Aβ.  Relative fluorescence was determined via ImageJ. Blots labelled with 
the aggregate forms they were exposed to in solution: (+) – positive with stock 
Aβ, (-) – negative control, probed with vehicle solution, M – monomeric 
sample, D/T – di/trimeric sample, O – oligomeric sample, I – insoluble sample. 
 
D/T                                O                                       I 
  +                      -                                             M     
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Table 3.1: ImageJ Analysis of Fig. 3.21. To convert a value to a pixel-inverted 








In this set of samples, it appears that the oligomeric aggregated Aβgave an 
enhanced signal of binding of the oligomers to the anchored GST-sAPPα.  
 
These studies used an antibody (6E10) that detected both the immobilised 
species and the probes of specific Aβ aggregates. It was planned to use then a 
specific antibody that would detect only Aβ (4G8) and not GST-sAPPα, 
moreover it was detecting the sequence that was involved in forming the 
aggregates and may have given misleading results. For this reason, 
disappointingly use of the specific antibody only detecting the binding species 














Positive 166.6 247.4 80.8 1.31 
Negative 185.9 247.4 61.5 1.0 
Mono 195.3 247.4 52.1 0.85 
Di/Tri 187.4 247.4 60.0 0.98 
Oligo 181.7 247.4 65.7 1.07 
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Fig. 3.23: Multiple replicates within a dot blot. Labelling of membranes as 
previous, insoluble sample was omitted.   
 
Four concurrent experiments using the dot blot method were performed in order 
to generate a large amount of data to further probe the experimental results so 
far. These however, omitted the insoluble condition as overall it was thought to 







  +           -              M      D/T    O   
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Table 3.2: ImageJ analysis of replicate dot-blot binding experiments 
(Figure 3.23). To convert a value to a pixel-inverted value “Inv” it was 








Ratio to Negative 
Control 
Negative 167.6 238.7 71.1 1 
Mono 183.8 238.7 54.8 0.77 
Di/Tri 184.0 238.7 54.7 0.77 
Oligo 182.9 238.7 55.8 0.79 








Ratio to Negative 
Control 
Negative 165.2 237.4 72.2 1 
Mono 128.8 237.4 108.6 1.50 
Di/Tri 132.1 237.4 105.3 1.46 
Oligo 149.6 237.4 87.8 1.22 








Ratio to Negative 
Control 
Negative 169.1 238.4 69.3 1 
Mono 175.2 238.4 63.2 0.91 
Di/Tri 187.8 238.4 50.7 0.73 
Oligo 181.7 238.4 56.8 0.82 
 
These results appeared to be fairly typical of the dot blot binding experiment. 
Positive control values were omitted from these tables as previously they 
appeared to hinder interpretation more than assist. The data from the first row 
of blots was omitted, due to the positive control reading as lower than the 
negative control. 
Table 3.3: Ratios to negative control taken from all previous binding 























Unfractionated 1.03 1.31 1.50 1.60 1.46 1.38 0.20 
Mono 0.95 0.85 0.77 1.50 0.91 1.00 0.26 
Di/Tri 0.92 0.98 0.77 1.46 0.73 0.97 0.26 




Fig. 3.24: Graph of average binding results of Aβ aggregates to GST-
sAPPα. Data has been taken from Table 3.3, showing relative binding ability of 
each aggregate form compared to negative control. Error bars derived from 
standard deviation in samples. 
 
Due to the highly variable nature of the results generated by this line of 
experimentation, it was difficult to draw any concrete conclusions from analysis 
of the data. This could be due to a number of factors, including the “enriched” 
but not “pure” nature of the fractionated samples as well as their ability to 
aggregate and disaggregate in solution during the course of the experiment. As 
such, it was known exactly which fraction was added into a binding 
experiment, but it is difficult to determine what sort of changes in aggregate 
state would occur over the course of the binding. This could have influenced 




























Chemiluminescence relative to Negative control
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3.2.6 Column separation of Aβ aggregates  
 
 
Fig. 3.25: Elution profile of Aβ aggregates separated on Superdex 75 
column utilising FPLC chromatography. Protein peaks were detected at 
215nm. Samples of the separated peaks (marked) were selected. Larger 
aggregated protein forms elute first from the column. 
 
Fig. 3.25 shows the elutions selected for further investigation. These were 
selected based on their distinct peaks at UV 215nm, suggesting they were 
distinct aggregate forms of Aβ. 
Fraction identifier 

































Fig. 3.26: Western blot of an SDS PAGE gel performed on the first five 
column peaks from Superdex elution of Aβ aggregates. Membrane was 
probed with 6e10 antibody detecting Aβ1-16 and showed visible protein in all 
five samples. 
 
As shown in Fig.3.26, it was possible to detect Aβ in the first five column 
elutions on a Western blot produced from an SDS PAGE gel. Unfortunately, 
these bands were more visible in the original image. Other column fractions did 














Marker size (kDa) 
M            Aβ           D10  E1  E5  E6  E9 
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3.2.7 Improved binding experiment 
 
A binding experiment was performed using the samples generated from the 
size-exclusion column as these samples would be more clearly resolved 
compared with those isolated from the earlier centrifugation protocol. Each 
isolated aggregate species of Aβ should be reasonably stable as they were 
eluted in an ammonium hydroxide solution, shown in the literature to have a 
stabilising effect on Aβ; preventing aggregation and disaggregation of samples 
in vitro. 
These fractions, compared with those used in the previous binding experiments 
that were only ‘enriched’ for the aggregate form of interest but still contained 
higher and lower order aggregates and monomers, should give more exact 
information as to the specific aggregates that show binding activity with GST-
sAPPα.  
The samples eluted from the size-exclusion column had their concentrations 
quantified by a modified BCA assay, as Aβ lacks reactive residues required for 
the original assay. When the BCA assay is run at a higher temperature (60°C) it 
is able to quantify amino acid bonds, so is better suited to Aβ quantification – 
especially compared to an Aβ control as was the case here. 
Fig. 3.27: Aβ standard curve generated by the modified BCA assay. Values 
measured in the assay had the average blank measurement subtracted and these 
were plotted against the concentration of each standard. 

























The concentration of each sample was determined using the line equation of the 
Aβ standard curve. First, the average absorbance from the three blank tubes was 
subtracted to get the net absorbance of the sample minus reagents. Then using 
the net absorbances as the y values, the line equation y=1.5385x + 0.0041 was 
solved for x, generating a concentration in mg/ml for each sample. The molarity 
of each sample was then calculated from the molecular weight of Aβ1-42 
(4514.04 kDa). Once all samples were quantified, an amount of each sample 
equivalent to 2μg of protein in solution was used in the dot blot binding 
protocol to determine each sample’s binding activity with GST-sAPPα. 
 
Table 3.4: Concentrations and molarities of samples produced from the 
size exclusion column. Concentrations were derived from the Aβ standard 
curve (Fig. 3.26). 
Sample ID Absorbance (562nm) Concentration (mg/ml) Molarity 
(μM) 
D10 0.212 0.072 15.9 
E1 0.199 0.063 14.05 
E5 0.16 0.038 8.43 
E6 0.161 0.039 8.58 
E9 0.167 0.043 9.44 
F3 0.19 0.056 12.75 
F8 0.12 0.012 2.67 
F11 0.132 0.020 4.40 
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Fig. 3.28: Dot blot binding results using samples of Aβaggregates 
generated from size exclusion column work. Three positive and negative 
controls were used to standardise results. Samples were labelled according to 
the fraction in which they eluted. 
 
Table 3.5: ImageJ analysis of improved binding experiment. To convert a 







The average value of the positive controls was taken and found to have a ratio 











D10 209.6 239.3 29.7 0.58 
E1 203.5 239.3 35.8 0.70 
E5 211.1 239.3 28.2 0.55 
E6 138.9 239.3 100.4 1.97 
E9 219.3 239.3 20.0 0.39 
F3 180.6 239.3 58.7 1.15 
F8 162.6 239.3 76.7 1.50 
F11 168.3 239.3 71.0 1.39 
D10        E1        E5       E6       E9      F3      F8      F11 
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Fig. 3.29: Graph of relative binding activity between Aβ fractions and 
GST-sAPPα compared to a negative control. Only samples E6, F3, F8 and 
F11 gave values above 1, indicating that binding activity may be localised to 
these fractions. 
 
As shown in Fig. 3.29, binding activity varied considerably between fractions 
of Aβ. Several samples (E6, F3, F8 and F11) showed an increase in 
chemiluminescence relative to the negative control, indicating that binding had 
taken place between the aggregate forms present in these fractions and GST-
sAPPα. This data suggests that there are a variety of Aβ aggregate forms that 
are capable of binding with sAPPα in-vitro, however more investigation is 
needed before a definite answer as to the size of these aggregates and their 
ability to bind in-vivo. Notably, the sample taken from fraction E6 showed an 





























In this project I aimed to characterise the binding relationship between the 
neuroprotective brain protein, sAPPα, and different aggregated forms of Aβ, 
neurotoxic when present in the brain at high concentrations. This has a context 
of a potential neuroprotective strategy against the development of Alzheimer’s 
disease. 
 
4.1 Production of GST-sAPP~ variants 
 
Available recombinant bacterial clones in the Tate research group were 
confirmed to express the fusion proteins GST-sAPPαand GST-
sAPPβrespectively at a high level. The GST fusion tag was an affinity label not 
only for purification of the species on Glutathione columns, but also for a solid 
phase strategy to assess interactions between the sAPPs and Aβ
Three temperature conditions were tested for production of the GST-sAPPs 
used in this study. Of the three temperatures used (18°C, 25°C and 37°C) both 
18 and 25°C produced comparable amounts of soluble protein (Fig. 3.2) 
compared to the protein in the insoluble fraction. Of these two, 18°C was 
chosen as the most convenient condition in further experiments, as it involved 







4.2 Purification of GST-sAPPα, GST-sAPPβ and MBP-
Aβ
 
GST-sAPPs were purified on glutathione affinity columns whereas MBP-Aβ 
was purified on an amylose affinity column utilising the N terminal fusion 
proteins that were recognised by the respective affinity ligands.  
For the GST- sAPPs, while not all the tagged protein bound on first pass of the 
crude bacterial protein lysate through the column, the flow through fraction 
could be recycled through the column to recover more of the particular GST-
sAPP being purified. Then non-specifically bound proteins were successfully 
removed generally with three washes and the GST proteins bound eluted with 
free glutathione giving a highly purified protein.  
For MBP–Aβ purification, the crude cell lysate was added to an amylose 
column to give a significantly purified fraction that could be eluted from the 
column by maltose and prepared for protease cleavage of the N terminal MBP 
subsequently by factor Xa protease. Although the yield was good, the 
anticipated need for large amounts of Aβ meant for the developmental studies I 
shifted to a commercial source.  
This meant all of the key reagents had been prepared for the sAPP/Aβ 






4.3 Investigation of an aberrant band in GST-sAPPs 
production gels 
 
As shown by the results of Westerns with an anti-GST antibody and a MALDI 
MS analysis, the aberrant bands appearing in certain production runs of GST-
sAPP proteins contained GST sequences. Here I speculate why this has 
happened. Possible theories are (i) either an aberrant minor translational 
initiation site within the GST sequence, has produced a shorter protein, or (ii) 
that in an aging culture containing pGEX plasmids, the translation of lengthy 
proteins becomes less effective and translation machinery tends to drop off of 
the plasmid during synthesis of the protein to produce a GST- truncated sAPP, 
or (iii) there has been an proteolytic cleavage post translation by an unknown 
protease. Each of these creates truncated versions of the fusion proteins of 
interest, containing part or all of the GST tags, which then show up as the 
aberrant band(s). It was not possible from the MALDI analysis to determine 
whether the N terminal region of GST was present as those peptides were not 
detected. 
 
4.4 Binding occurs between Aβ and GST-sAPPα in vitro 
 
The glutathione column was then used to attach first the GST-sAPPα as bait, 
and then add Aβ as for the prey; that in this case was Aβ. Bait and bound prey 
could then be released from the column by external application of glutathione 
and co-eluted, As can be seen in fig. 3.11, there is a clear evidence of co-elution 
of GST-sAPPα and Aβ from the Sepharose column. As seen in fig. 3.10, this 
co-elution takes place after all unbound protein has been washed from the 
column after addition of each separate protein, indicating that this co-elution is 
a valid conclusion of interaction with the bound GST sAPPα. This indicates 
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that GST-sAPPα and Aβ bind in-vitro and thus have the potential to bind in-
vivo assuming there are no physiological factors that prevent this. This finding 
is consistent with previous work performed by the Tate Lab (Thomsen, 2012).  
 
4.5 Binding occurs between Aβ and GST-sAPPβ in vitro 
 
As shown in Fig. 3.13 GST-sAPPβ and Aβ also co-elute from the glutathione 
column in a similar manner to Aβ and GST-sAPPα, after all non-bound protein 
has been washed from the column. This has been observed previously by 
members of the Tate lab but at much lower efficiency (Thomsen, 2012). 
 
4.6 No observable binding occurs between GST and Aβ  
 
As a negative control GST, expressed in E. coli and purified on glutathione 
columns, was also used as the bait ligand to attempt to bind Aβ. In Fig. 3.14, it 
can be seen that no Aβ was present in the elution fraction of this experiment. 
This indicates that the GST tag on sAPPα and Aβ are not the reason for the co-
elution and therefore do not have a binding relationship in-vitro. The 
significance of this is two-fold. It shows that the binding observed for the GST 
fusion proteins used in these experiments is due to the presence of the sAPP 
sequence and not GST. This also shows that Aβ does have specific binding 
partners and does not appear to readily bind with any protein present in 
solution. Together these data consolidate the results so far and show the nature 
of the binding relationship between these proteins as it exists in vitro. 
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4.6 Aggregation of Aβ 
 
Aβ has been shown to readily aggregate, both in vitro and in vivo. This 
underpins a large amount of Alzheimer’s disease pathology and so to 
understand the binding relationships between Aβ and its partners, more 
information is needed on the various aggregate forms and the part they play in 
these relationships. This is relevant for identifying which aggregate form binds 
to a given protein; as well as the greater understanding this gives to known 
relationships between Aβ and other proteins in normal biological and 
pathological contexts. 
With this in mind, aggregate-rich samples of Aβ were generated for use in 
further experimentation, as well as methods to separate these aggregates into 
size classes so that they could be individually analysed for their relative binding 
ability with GST-sAPPα. 
 
4.6.1 Analysing the occurrence of aggregates of Aβ 
 
As shown in fig. 3.15 a native-PAGE gel shows a wide range of aggregate 
levels present in a sample, which in fig. 3.16 by contrast on the SDS-PAGE gel, 
typically used to analyse aggregates, they are not visible. Due to the 
dissociating nature of the SDS gel, larger aggregates appear to be lost either in 
sample preparation or the gel itself – despite literature sources suggesting that 
SDS itself is an aggregating agent of Aβ! This result is interesting, considering 
the considerable weight given to SDS-PAGE gel as an analytical tool for 
aggregation of Aβ in the literature. These results suggest that the aggregate 





4.6.2 Aggregation and disaggregation tests with Aβ 
 
As shown in fig. 3.17, established Aβ disaggregation protocols used previously 
with SDS-PAGE gel resolution methods have been shown in this study to be 
less effective than previously thought. These methods generated gel profiles 
that suggested a decrease in monomeric species vs high order aggregates, but 
whether it was by loss of monomeric species or enhancement of higher 
aggregation states is currently unclear. What is clear, however, is that 
previously accepted methods using dissociating PAGE gels must be re-
examined as they may be vastly underestimating the variety and size of 
aggregate species in a “disaggregated” sample and any conclusions built upon 
the use of purely monomeric species of Aβ may be flawed. 
 
4.6.3 Centrifuge separation of aggregates 
 
Using high-speed ultracentrifuge separation, it was possible to collect samples 
containing roughly discrete fractions of the aggregate forms of interest to this 
study (Fig. 3.18). These samples were enriched rather than discrete preparations 
of monomer, dimer/trimer, oligomer and higher order fractions and so were 
appropriate for analysis in this initial phase of the study. While individually 
these samples may not give absolutely distinct results, the enrichment of each 
particular aggregate level would allow for broad trends to be observed when 
compared to positive and negative controls in later experiments. 
 
As can be seen in fig. 3. 18, the centrifuge separation method was successful for 
these purposes. In the literature (Selkoe, 2011) it was shown that species of Aβ 
associate and dissociate with higher order aggregate levels in solution as part of 
a normal development in Alzheimer’s pathology. Unless steps are taken to 
prevent both upward aggregation and downward disaggregation in these 
86 
 
samples, it is impossible to generate samples containing a single aggregate level 
using this or any other method.  
 
4.6.4 Western blot binding experiments 
 
As shown in fig. 3.19 and 3.20, despite enough protein both bound to the 
membrane and free in solution to be visible when probed with the 6e10 
antibody, there is a lack of visible bands to suggest whether or not binding is 
taking place. It is currently unclear why this was so, with the method being 
established in the literature as suitable for similar applications in testing protein 
binding characteristics. Despite this, the result inspired development of a more 
effective and less time-consuming binding test that was used for the following 
experiments of this study. 
 
4.6.4 Dot blot binding experiments using centrifugally separated samples 
 
This method was an attempt to better quantify the relative binding ability of 
GST-sAPPα with several aggregation states of Aβ. Using the samples generated 
from the ultracentrifugation of unfractionated Aβ, it was thought that the 
relative discreteness of the aggregate forms would allow broad conclusions to 
be drawn, which could then be investigated with other methods.  
In practice, it appeared that the results were too similar between aggregate 
samples for any concrete conclusions to be formed. The unfractionated sample 
appears to have a higher binding affinity than any given discrete aggregate 
sample, while being at the same concentration, which may suggest that the 
ability of Aβ to associate and dissociate into higher and lower aggregate forms 
may be playing a part in these results.  
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While roughly discrete, the samples produced by the ultracentrifugation method 
did contain other aggregation states of Aβ, so it was difficult at this stage to 
pinpoint if any singular aggregate form had a higher binding affinity than any 
other. 
These data give some insight into the binding characteristics of Aβ and sAPPα 
but more refined methods of separating aggregate forms and testing binding are 
needed to evaluate further. 
 
4.6.5 Separation of aggregates on a size exclusion column 
 
Following a finding by Esparza et al 2016, that elution into ammonium 
hydroxide allowed the preservation of aggregate forms resolved by size 
exclusion chromatography, a method was generated whereby aggregates were 
produced and then immediately separated via elution from a size exclusion 
column by ammonium hydroxide (pH10.5). This could be utilised in order to 
generate cleaner, more discrete samples of aggregates so as to better quantify 
the binding behaviour between sAPPα and Aβ. It was therefore hoped that this 
method would be more effective for use in this study. 
In the limited time available I was able to show that this method is able to 
resolve several fractions from a stock solution of aggregated Aβ, based on the 
absorbance profile. Puzzlingly, give the amount of protein taken for the 
fractionation it was, however, difficult to visually resolve these fractions using 
native PAGE gels or Western blots. Most likely due to either sample loss due to 
transferring between tubes, or the wider spread that native-page gels exhibit due 
to their non-dissociating nature. Resolving individual bands is more difficult in 
a multiple aggregation state sample such as Aβ. While SDS-Page gels do not 
suffer from the resolution issue, they are unable to show the aggregate forms 
that are present in a given sample due to the fact they do indeed dissociate the 
separated aggregate fractions. This means that a sample can be successfully 
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probed for the presence of Aβ, but some interpretation of the size exclusion 
absorbance pattern is required to determine the size of the original aggregate in 
the sample. However, based on a native-page profile of the full spectrum of Aβ 
aggregates that could be present in a sample, taken from running the stock Aβ, 
and performing a Western analysis using the specific 6e10antibody, it might be 
possible to gain an estimate of the aggregate forms present in a given sample. 
 
4.6.6 Improved binding experiment 
 
Using samples generated from the size exclusion column separation of Aβ it 
was possible to recreate the dot-blot binding experiment with a more specific 
sample set. Theoretically, combined with the NH4OH elution from the size-
exclusion column, the samples generated should be relatively discrete fractions 
containing a stable aggregate form of Aβ. It can be seen in Fig. 3.27 and Table 
3.6 that the binding experiment results appeared comparable to those performed 
previously.  
Several conclusions can be made from these results- there is the need for more 
replications of the experiment. Due to the factors of time and protein resources, 
only one attempt at the improved binding experiment has been possible thus far, 
more will be needed to corroborate the findings here.  Another observation is 
the effect of the final NH4OH concentration on the binding efficacy between 
GST-sAPPα and Aβ. As there was no practical way to remove the NH4OH from 
the protein solutions eluted from the size-exclusion column without 
encouraging a change in the aggregation state of these samples, the 2μg of 
protein added from each sample was contained in a highly variable volume of 




While it appears that NH4OH prevents binding between Aβ, it does not seem to 
affect activity between Aβ and GST-sAPPα, as those fractions with the highest 
binding activity had both high and low amounts of NH4OH in solution.  
Four of the column-separated aggregate fractions showed a ratio with the 
negative control greater than 1, indicating binding may be taking place in-vitro. 
Taking into consideration the fact that larger aggregates will be fractionated by 
the size-exclusion column first, a comparison to a profile of Aβ aggregates can 
be made with the samples separated in this study. For example, working under 
the assumption that the sample F11 is the smallest form of Aβ, the monomeric 
form and constructing upwards in size using Fig. 3.15[A] as a guide for the 
possible aggregate forms an estimate of the aggregate form present in each 
sample can be constructed with a reasonable degree of confidence. 
 
Fig. 4.1: Column separated aggregate fractions aligned with a known 
profile of Aβ aggregates. Aggregate profile taken from: Cerf, et al., 2009. 
Reused with permission. Size-exclusion fractions arranged from smallest (F11) 






D10, E1, E5 Oligomeric 
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As shown in Fig. 4.1, assuming fraction F11 is the monomeric form of Aβ as it 
is the smallest form eluted from the column, an estimation of the larger 
aggregate forms fractionated by the column can be constructed. Without further 
testing, it is difficult to know for sure which aggregate forms are present for 
certain, but with this estimate it appears that increased binding activity is shown 
between Aβ and GST-sAPPα in-vitro when the Aβ is in the monomeric, 
dimeric and trimeric forms. Larger oligomeric forms: D10, E1, E5 and E9 
exhibited less binding activity in this assay, with the exception of fraction E6, 
which appears to be a class of soluble oligomeric Aβ. Based on these data, it 
appears that there is a specificity in the binding between Aβ and sAPPα, 
mediated by the aggregation state of Aβ, at least in-vitro. Larger aggregates of 
Aβ appear not to interact with sAPPα in this assay, suggesting that perhaps in-
vivo these aggregate forms are unable to be sequestered by sAPPα in the 
neuroprotective pathway. Further investigation is required to determine the true 
binding partner of sAPPα in the actual brain environment. 
 
4.7 Future directions 
 
It was hoped that after preliminary analysis of the binding between the 
fractionated aggregate species and sAPPα, time would have allowed the 
analysis to be adapted to and repeated with a more robust platform using small 
amounts of glutathione resin in Eppendorf tubes. For this, GST- sAPPα (as well 
as the GST-sAPPβ and GST controls) would be immobilised and exposed to 
each aggregate form. The beads would then be washed and treated with elution 
buffer as in the previously established protocol. The eluted products would then 
be examined by Western blotting with antibodies recognising: i) The sequence 
from the front half of Aβ, which is homologous with that of sAPPα’s C-
terminal 16 amino acids, ii) The sequence from the back half of Aβ, which is 
specific to Aβ. 
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Aβ and sAPPα are well separated by SDS-PAGE so it would be easy to 




Herein, I attempted to better characterise and understand the binding 
relationship between Aβ and sAPPα. A mechanism in the human brain that 
putatively appears to protect against the formation of Alzheimer’s disease. This 
mechanism, if fully understood, could serve to be the springboard for a range of 
therapies targeting the early stages of Alzheimer’s disease formation and could 
improve the quality of life for an untold number of future sufferers. In addition 
to reducing the impact of the disease on the individual, a successful therapy 
would save (at current estimates) one trillion dollars worldwide per annum in 
care associated costs that are currently being spent on maintaining rapidly 
degenerating patients. The social burden of caring for those that develop 
Alzheimer’s disease would likewise be alleviated, allowing better working 
opportunities for family members or others that are currently tied up in caring 
for those with Alzheimer’s. 
Based on my results, several candidates for the main in vitro binding partner of 
sAPPα have been identified. With more experimentation, these forms of Aβ can 
be characterised and investigated further.  
This study attempts to better understand the underlying mechanism for the 
neuroprotective action of sAPPα against Alzheimer’s disease as well as its 
ability to rescue mice models in the early stages of this disease. Based on these 
results, it appears that sAPPα has the ability to bind to and clear several 
neurotoxic species of Aβ, which may interact with Aβ’s ability to build up in 
insoluble plaque reservoirs. In theory, as the lower levels of aggregates are 
cleared by sAPPα, the higher levels of aggregates are forced to disaggregate to 
maintain the equilibrium between soluble and insoluble Aβ. This in turn would 
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reduce the size and number of insoluble plaques and may over time be able to 
bring the concentration of Aβ down below its aggregation threshold entirely.  
 
This study is not without its limitations, as time became a factor, the final 
binding experiment was not able to be repeated, further repeats are necessary in 
order to definitively prove the results of this study. The dot blot assay was 
originally planned for use with a specific antibody for Aβ, but that antibody 
gave large backgrounds and proved unsuitable – hence the assay had to be used 
with an antibody that recognised both sAPPα and Aβ, then looking for 
enhancement of signal on Aβ binding. In addition, it was not possible to 
visually resolve each aggregate form on a native-page gel or a western blot 
membrane, potentially due to low concentrations of protein or the effects of the 
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Appendix I: Chemicals and Reagents 
 
All chemicals are of analytical grade unless specified 
 
Amersham Biosciences, Sweden: 
     HiTrap® desalting column 
Applichem GmBH, Germany: Isopropyl β-D-thiogalactopyranoside (IPTG) 
    N,N,N’,N’-tetramethyl-ethylenediamine 
    (TEMED) 
Bio-rad Laboratories, USA: 30% acrylamide/bis 37.5:1 
    Ammonium persulphate (APS) 
    Broad-range SDS PAGE molecular weight 
       standard 
    ClarityTM Western ECL Substrate 
    Nitrocellulose membrane (0.2 + 0.44µm) 
BioFroxx GmBH, Germany: Glycine (Glycin zur Analyse) 
    Tris (Tris Xtrapure für die Biochemie) 
Biolab, Australia:   Glycerol 
GE Healthcare, UK:  Superdextm 75 10/300 GL column 
    Glutathione 4b sepharose beads 
    PVDF (Polyvinylidene fluoride) membrane 
    (0.2µm) 
Greiner Bio-One International GmBH, Austria: 
    15ml and 50ml sterile Falcon® tubes 
104 
 
Lab supply, New Zealand:  Ethanol 
Merk, Germany:  Methanol 
    Peptone from Caseine (Tryptone) 
    Sodium Chloride 
    Granulated yeast extract 
New England Biolabs, USA Amylose Resin 
Pam’s, New Zealand:  Skim milk powder 
 
Scharlau, Spain:  Acetic acid 
    Ethylenediaminetetraacetic acid (EDTA) 
Sigma Aldrich – Life Science, USA:  
    2-Mercaptoethanol 
    Ampicillin sodium salt 
    Brilliant blue R-250 coomassie stain 
    Tween20TM 





Appendix II: Media, Buffers and Solutions 
 
All solutions were prepared using MilliQTM water or ddH2O.Where required, 
solutions were sterilised by autoclaving (15 PSI 120°C, 15mins) or filtered 
through a 0.2μm filter. 
 
Ampicillin stock 
 Ampicillin sodium salt  100 mg/ml 
Chloramphenicol stock 
 Chloramphenicol   50 mg/ml 
 EtOH     100% (v/v) 
Lysogeny Broth (LB) 
 Peptone    1% (w/v) 
 Yeast extract    0.5% (w/v) 
 NaCl     1% (w/v) 
2YT media 
 Peptone    1.6% (w/v) 
 Yeast extract    1% (w/v) 
 NaCl     0.5% (w/v) 
1× Phosphate buffered saline (PBS) 
 NaH2PO4    80 mM 
 Na2H2PO4    20 mM 
 NaCl     100 mM 
0.1× PBS 
 1× PBS    10% (v/v) 
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Tris-buffered saline (TBS) 
 Tris-HCl (pH 7.5)   50 mM 
 NaCl     150 mM 
3× SDS PAGE Cracking buffer 
 Tris-HCl (pH 6.8)    250 mM 
 SDS     49 mM 
 Urea     6 M 
 Brilliant blue R-250    0.04% (w/v) 
 2-mercaptoethanol    1% (w/v) 
4× SDS separating gel buffer 
 SDS     14 mM 
 Tris-HCl (pH 6.8)   3 M 
4× SDS stacking gel buffer 
 SDS     14 mM 
 Tris-HCl (pH 6.8)   0.5 M 
10× SDS inner running buffer 
 SDS     28 mM 
 Tris     250 mM 
SDS outer running buffer 
 Tris     250 mM 
 Glycine    0.19 M 
Coomassie stain 
 Brilliant blue R-250   0.25% (w/v) 
 Methanol    45% (v/v) 




Colloidal Coomassie stain 
 Ammonium sulphate   10% (w/v) 
 Brilliant blue R-250   0.1% (w/v) 
 Ethanol    20% (v/v) 
 Ortho-phosphoric acid  3% (v/v) 
Coomassie destaining solution 
 Methanol    5% (v/v) 
 Acetic acid    7.5% (v/v) 
10× Transfer buffer 
 Tris     250 mM 
 Glycine    1.92 M 
1× Transfer buffer (Working solution) 
 10× Transfer buffer   10% (v/v) 
 Methanol     20% (v/v) 
Ponceau S stain 
 Ponceau S    0.5% (w/v) 
 Acetic acid    5% (v/v) 
PBS/TBS-Tween20tm 
 PBS/TBS    99.9% (v/v) 
 Tween20tm    0.1% (v/v) 
Affinity Chromatography Buffer 
 Tris-HCl (pH 7.5)   20 mM 
 NaCl     0.2 M 
Elution buffer (Amylose resin) 
 Tris-HCl (pH 7.5)   20 mM 
 NaCl     0.2 M 
 Maltose    10 mM 
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Elution buffer (Glutathione sepharose resin) 
 Tris-HCl (pH 8.0)   50 mM 
 Reduced glutathione   50 mM 
Isopropyl β-D-1-thiogalactopyranoside solution (IPTG) 
 IPTG     1 M 
Factor Xa protease cleavage buffer 
 Tris-HCl (pH 6.5)   20 mM 
  NaCl     50 mM 
  CaCl2     1 mM 
native PAGE resolving buffer 
  Tris-HCl (pH 8.8)   3 M 
native PAGE stacking buffer 
  Tris-HCl (pH 6.8)   500 mM 
10× native PAGE running buffer 
  Tris     250 mM 
  Glycine    1.9 M 
6× native PAGE loading buffer 
  Tris-HCl    125 mM 
 Glycerol    20% (v/v) 








Appendix III: Instruments and Equipment 
 
A list of instruments and equipment used in the course of this study. 
 
Astell Scientific Ltd, UK: Autoclave AMA270T 
Beckman Coulter Life Sciences, USA: Centrifuge Avanti J26S-XP 
 250ml Rotor F250 (F14BCI-
6x250y) 
 50ml Falcon Rotor F50C (F14BCI-
14x50cy) 
Biochrom, UK: Spectrophotometer Ultrospec II 
Biolab Scientific Ltd, Canada: Centrifuge 5415D, Eppendorf 
Bio-Rad Laboratories, Inc., USA: Powerpack  Power Pac 300 
 PAGE gel system Mini-Protean® II 




GE Heathcare, USA; Epson, Japan: PAGE gel scanner Imagescanner III 
Grant Instruments, UK Water bath Water bath 
Mettler Toledo, USA: Digital scale Deltarange® PJ360 
New Brunswick Scientific, USA: Incubator/shaker Innova®40 
Select Bioproducts, USA: Rocker Rock-it Platform 
Rocker 
Thermo Fisher Scientific, USA: Nanodrop® Nanodrop® ND-
1000 
 Assay plate scanner Multiskan GO 
Sonics, USA Sonicator Vibracell 
